JP2022524759A - Shp2アンタゴニストとしてのカルボキサミド-ピリミジン誘導体 - Google Patents
Shp2アンタゴニストとしてのカルボキサミド-ピリミジン誘導体 Download PDFInfo
- Publication number
- JP2022524759A JP2022524759A JP2021553031A JP2021553031A JP2022524759A JP 2022524759 A JP2022524759 A JP 2022524759A JP 2021553031 A JP2021553031 A JP 2021553031A JP 2021553031 A JP2021553031 A JP 2021553031A JP 2022524759 A JP2022524759 A JP 2022524759A
- Authority
- JP
- Japan
- Prior art keywords
- amino
- pyrimidine
- carboxamide
- dichlorophenyl
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 101710116241 Tyrosine-protein phosphatase non-receptor type 11 Proteins 0.000 title description 49
- 102100033019 Tyrosine-protein phosphatase non-receptor type 11 Human genes 0.000 title description 49
- 239000005557 antagonist Substances 0.000 title description 7
- 150000001875 compounds Chemical class 0.000 claims abstract description 358
- 150000003839 salts Chemical class 0.000 claims abstract description 66
- 238000011282 treatment Methods 0.000 claims abstract description 29
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 6
- -1 C 1 -C 3 alkoxy Chemical group 0.000 claims description 151
- 238000000034 method Methods 0.000 claims description 62
- 206010028980 Neoplasm Diseases 0.000 claims description 40
- 239000003814 drug Substances 0.000 claims description 40
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 claims description 35
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 33
- 201000011510 cancer Diseases 0.000 claims description 32
- 239000003112 inhibitor Substances 0.000 claims description 30
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 24
- HKSQZEGSMBFHGC-UHFFFAOYSA-N pyrimidine-4-carboxamide Chemical compound NC(=O)C1=CC=NC=N1 HKSQZEGSMBFHGC-UHFFFAOYSA-N 0.000 claims description 24
- RGSFGYAAUTVSQA-UHFFFAOYSA-N Cyclopentane Chemical compound C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 claims description 18
- 125000004432 carbon atom Chemical group C* 0.000 claims description 18
- 201000010099 disease Diseases 0.000 claims description 18
- 229940124597 therapeutic agent Drugs 0.000 claims description 18
- 125000000623 heterocyclic group Chemical group 0.000 claims description 16
- 125000006697 (C1-C3) aminoalkyl group Chemical group 0.000 claims description 15
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 15
- 125000000217 alkyl group Chemical group 0.000 claims description 15
- 208000035475 disorder Diseases 0.000 claims description 15
- 125000001424 substituent group Chemical group 0.000 claims description 15
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 14
- 125000006699 (C1-C3) hydroxyalkyl group Chemical group 0.000 claims description 11
- 125000003118 aryl group Chemical group 0.000 claims description 11
- 201000001441 melanoma Diseases 0.000 claims description 11
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 10
- 239000002671 adjuvant Substances 0.000 claims description 10
- 125000001246 bromo group Chemical group Br* 0.000 claims description 10
- 206010017758 gastric cancer Diseases 0.000 claims description 10
- 125000001072 heteroaryl group Chemical group 0.000 claims description 10
- 201000011549 stomach cancer Diseases 0.000 claims description 10
- 125000004122 cyclic group Chemical group 0.000 claims description 9
- DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Natural products C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 claims description 9
- 230000003211 malignant effect Effects 0.000 claims description 9
- 125000003003 spiro group Chemical group 0.000 claims description 9
- 206010006187 Breast cancer Diseases 0.000 claims description 8
- 208000026310 Breast neoplasm Diseases 0.000 claims description 8
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 8
- 125000002619 bicyclic group Chemical group 0.000 claims description 8
- 125000004188 dichlorophenyl group Chemical group 0.000 claims description 8
- 125000002950 monocyclic group Chemical group 0.000 claims description 8
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 8
- 210000001519 tissue Anatomy 0.000 claims description 8
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 8
- 206010009944 Colon cancer Diseases 0.000 claims description 7
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 7
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 7
- 206010041067 Small cell lung cancer Diseases 0.000 claims description 7
- 229910052799 carbon Inorganic materials 0.000 claims description 7
- 201000004101 esophageal cancer Diseases 0.000 claims description 7
- 201000005202 lung cancer Diseases 0.000 claims description 7
- 208000020816 lung neoplasm Diseases 0.000 claims description 7
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 7
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 7
- 208000000587 small cell lung carcinoma Diseases 0.000 claims description 7
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 6
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 6
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical group C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims description 6
- 206010039491 Sarcoma Diseases 0.000 claims description 6
- 229910052794 bromium Inorganic materials 0.000 claims description 6
- 208000005017 glioblastoma Diseases 0.000 claims description 6
- 201000010536 head and neck cancer Diseases 0.000 claims description 6
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 6
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 6
- 201000008968 osteosarcoma Diseases 0.000 claims description 6
- 201000002528 pancreatic cancer Diseases 0.000 claims description 6
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 6
- 230000037361 pathway Effects 0.000 claims description 6
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 5
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 5
- 206010038389 Renal cancer Diseases 0.000 claims description 5
- 229950002916 avelumab Drugs 0.000 claims description 5
- 229940082789 erbitux Drugs 0.000 claims description 5
- 201000010982 kidney cancer Diseases 0.000 claims description 5
- 230000002062 proliferating effect Effects 0.000 claims description 5
- 230000009885 systemic effect Effects 0.000 claims description 5
- AHYMHWXQRWRBKT-UHFFFAOYSA-N tepotinib Chemical compound C1CN(C)CCC1COC1=CN=C(C=2C=C(CN3C(C=CC(=N3)C=3C=C(C=CC=3)C#N)=O)C=CC=2)N=C1 AHYMHWXQRWRBKT-UHFFFAOYSA-N 0.000 claims description 5
- 229950009455 tepotinib Drugs 0.000 claims description 5
- 206010029260 Neuroblastoma Diseases 0.000 claims description 4
- 208000017442 Retinal disease Diseases 0.000 claims description 4
- 206010038923 Retinopathy Diseases 0.000 claims description 4
- 150000001602 bicycloalkyls Chemical group 0.000 claims description 4
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 4
- 210000002865 immune cell Anatomy 0.000 claims description 4
- OSTNOOSXOQHKOQ-UHFFFAOYSA-N 2-(4-amino-4-methylpiperidin-1-yl)-5-(2,3-dichlorophenyl)-6-methylpyrimidine-4-carboxamide Chemical compound NC1(CCN(CC1)C1=NC(=C(C(=N1)C(=O)N)C1=C(C(=CC=C1)Cl)Cl)C)C OSTNOOSXOQHKOQ-UHFFFAOYSA-N 0.000 claims description 3
- VIBUVLIOJVFFHR-UHFFFAOYSA-N 2-(4-amino-4-methylpiperidin-1-yl)-5-(2,3-dichlorophenyl)-6-oxo-1H-pyrimidine-4-carboxamide Chemical compound NC1(CCN(CC1)C1=NC(=C(C(=N1)C(=O)N)C1=C(C(=CC=C1)Cl)Cl)O)C VIBUVLIOJVFFHR-UHFFFAOYSA-N 0.000 claims description 3
- SAITWYGSDMTAQF-UHFFFAOYSA-N 2-(4-amino-4-methylpiperidin-1-yl)-6-chloro-5-(3-fluorophenyl)pyrimidine-4-carboxamide Chemical compound NC1(CCN(CC1)C1=NC(=C(C(=N1)C(=O)N)C1=CC(=CC=C1)F)Cl)C SAITWYGSDMTAQF-UHFFFAOYSA-N 0.000 claims description 3
- SCCZIRSIZZLTSR-KPZWWZAWSA-N 2-[(3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-5-(2,3-dichlorophenyl)-6-methylpyrimidine-4-carboxamide Chemical compound N[C@@H]1[C@@H](OCC11CCN(CC1)C1=NC(=C(C(=N1)C(=O)N)C1=C(C(=CC=C1)Cl)Cl)C)C SCCZIRSIZZLTSR-KPZWWZAWSA-N 0.000 claims description 3
- NQVSZXBKPZLKMM-UHFFFAOYSA-N 6-amino-2-(4-amino-4-methylpiperidin-1-yl)-5-(2,3-dichlorophenyl)-N-hydroxypyrimidine-4-carboxamide Chemical compound ONC(=O)C1=NC(=NC(=C1C1=C(C(=CC=C1)Cl)Cl)N)N1CCC(CC1)(C)N NQVSZXBKPZLKMM-UHFFFAOYSA-N 0.000 claims description 3
- OYYCMKZHVREVIU-UHFFFAOYSA-N 6-amino-2-(4-amino-4-methylpiperidin-1-yl)-5-(2,3-dichlorophenyl)pyrimidine-4-carbohydrazide Chemical compound NC1=C(C(=NC(=N1)N1CCC(CC1)(C)N)C(=O)NN)C1=C(C(=CC=C1)Cl)Cl OYYCMKZHVREVIU-UHFFFAOYSA-N 0.000 claims description 3
- CJJNYOYYLGSMNP-UHFFFAOYSA-N 6-amino-2-(4-amino-4-methylpiperidin-1-yl)-5-(2,3-dichlorophenyl)pyrimidine-4-carboxamide Chemical compound NC1=C(C(=NC(=N1)N1CCC(CC1)(C)N)C(=O)N)C1=C(C(=CC=C1)Cl)Cl CJJNYOYYLGSMNP-UHFFFAOYSA-N 0.000 claims description 3
- TWIOBPIJJIJRNM-UHFFFAOYSA-N 6-amino-2-(4-amino-4-methylpiperidin-1-yl)-5-(3-chlorophenyl)pyrimidine-4-carboxamide Chemical compound NC1=C(C(=NC(=N1)N1CCC(CC1)(C)N)C(=O)N)C1=CC(=CC=C1)Cl TWIOBPIJJIJRNM-UHFFFAOYSA-N 0.000 claims description 3
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 3
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims description 3
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 3
- 208000006468 Adrenal Cortex Neoplasms Diseases 0.000 claims description 3
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 3
- 206010005003 Bladder cancer Diseases 0.000 claims description 3
- 201000009030 Carcinoma Diseases 0.000 claims description 3
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 3
- 208000011231 Crohn disease Diseases 0.000 claims description 3
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 3
- 102100031480 Dual specificity mitogen-activated protein kinase kinase 1 Human genes 0.000 claims description 3
- 101710146526 Dual specificity mitogen-activated protein kinase kinase 1 Proteins 0.000 claims description 3
- 206010014733 Endometrial cancer Diseases 0.000 claims description 3
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 3
- 206010015150 Erythema Diseases 0.000 claims description 3
- 208000017604 Hodgkin disease Diseases 0.000 claims description 3
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 3
- 208000037147 Hypercalcaemia Diseases 0.000 claims description 3
- 206010021143 Hypoxia Diseases 0.000 claims description 3
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 3
- 208000007766 Kaposi sarcoma Diseases 0.000 claims description 3
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims description 3
- 208000028018 Lymphocytic leukaemia Diseases 0.000 claims description 3
- 206010025323 Lymphomas Diseases 0.000 claims description 3
- 229940124647 MEK inhibitor Drugs 0.000 claims description 3
- 208000034578 Multiple myelomas Diseases 0.000 claims description 3
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 3
- 206010033128 Ovarian cancer Diseases 0.000 claims description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 3
- 239000012271 PD-L1 inhibitor Substances 0.000 claims description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 3
- 208000008601 Polycythemia Diseases 0.000 claims description 3
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 3
- 206010060862 Prostate cancer Diseases 0.000 claims description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 3
- 201000004681 Psoriasis Diseases 0.000 claims description 3
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 3
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 3
- 208000021712 Soft tissue sarcoma Diseases 0.000 claims description 3
- 208000024313 Testicular Neoplasms Diseases 0.000 claims description 3
- 206010057644 Testis cancer Diseases 0.000 claims description 3
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 3
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 3
- 208000008385 Urogenital Neoplasms Diseases 0.000 claims description 3
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 3
- 206010047115 Vasculitis Diseases 0.000 claims description 3
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 claims description 3
- 208000008383 Wilms tumor Diseases 0.000 claims description 3
- 201000002454 adrenal cortex cancer Diseases 0.000 claims description 3
- 125000002618 bicyclic heterocycle group Chemical group 0.000 claims description 3
- 125000004452 carbocyclyl group Chemical group 0.000 claims description 3
- 201000010881 cervical cancer Diseases 0.000 claims description 3
- 208000037976 chronic inflammation Diseases 0.000 claims description 3
- 230000006020 chronic inflammation Effects 0.000 claims description 3
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims description 3
- 208000019425 cirrhosis of liver Diseases 0.000 claims description 3
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 claims description 3
- 230000007850 degeneration Effects 0.000 claims description 3
- 229940121647 egfr inhibitor Drugs 0.000 claims description 3
- 231100000321 erythema Toxicity 0.000 claims description 3
- 201000009277 hairy cell leukemia Diseases 0.000 claims description 3
- 230000000148 hypercalcaemia Effects 0.000 claims description 3
- 208000030915 hypercalcemia disease Diseases 0.000 claims description 3
- 206010020718 hyperplasia Diseases 0.000 claims description 3
- 230000007954 hypoxia Effects 0.000 claims description 3
- 208000003747 lymphoid leukemia Diseases 0.000 claims description 3
- 201000000564 macroglobulinemia Diseases 0.000 claims description 3
- 208000025854 malignant tumor of adrenal cortex Diseases 0.000 claims description 3
- 208000025113 myeloid leukemia Diseases 0.000 claims description 3
- 201000008026 nephroblastoma Diseases 0.000 claims description 3
- 210000000056 organ Anatomy 0.000 claims description 3
- 208000021255 pancreatic insulinoma Diseases 0.000 claims description 3
- 229940121656 pd-l1 inhibitor Drugs 0.000 claims description 3
- 201000007914 proliferative diabetic retinopathy Diseases 0.000 claims description 3
- 208000015347 renal cell adenocarcinoma Diseases 0.000 claims description 3
- 230000002207 retinal effect Effects 0.000 claims description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 3
- 201000000849 skin cancer Diseases 0.000 claims description 3
- 201000003120 testicular cancer Diseases 0.000 claims description 3
- NQRYJNQNLNOLGT-UHFFFAOYSA-N tetrahydropyridine hydrochloride Natural products C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims description 3
- 206010043554 thrombocytopenia Diseases 0.000 claims description 3
- 201000002510 thyroid cancer Diseases 0.000 claims description 3
- 210000001685 thyroid gland Anatomy 0.000 claims description 3
- 238000002054 transplantation Methods 0.000 claims description 3
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 3
- 208000037964 urogenital cancer Diseases 0.000 claims description 3
- 230000002792 vascular Effects 0.000 claims description 3
- NHQKLPQAVFDJLQ-UHFFFAOYSA-N 2-(4-amino-4-methylpiperidin-1-yl)-5-(2,3-dichlorophenyl)pyrimidine-4-carboxamide Chemical compound NC1(CCN(CC1)C1=NC=C(C(=N1)C(=O)N)C1=C(C(=CC=C1)Cl)Cl)C NHQKLPQAVFDJLQ-UHFFFAOYSA-N 0.000 claims description 2
- VZAWBEPGIGHBCI-UHFFFAOYSA-N 2-(4-amino-4-methylpiperidin-1-yl)-6-chloro-5-(2,3-dichlorophenyl)pyrimidine-4-carboxamide Chemical compound NC1(CCN(CC1)C1=NC(=C(C(=N1)C(=O)N)C1=C(C(=CC=C1)Cl)Cl)Cl)C VZAWBEPGIGHBCI-UHFFFAOYSA-N 0.000 claims description 2
- QGPUYYQGSISMSB-UHFFFAOYSA-N 2-(4-amino-4-methylpiperidin-1-yl)-6-fluoro-5-(3-fluorophenyl)pyrimidine-4-carboxamide Chemical compound NC1(CCN(CC1)C1=NC(=C(C(=N1)C(=O)N)C1=CC(=CC=C1)F)F)C QGPUYYQGSISMSB-UHFFFAOYSA-N 0.000 claims description 2
- IWMGAWPGQYIEED-UHFFFAOYSA-N 6-amino-2-(4-amino-4-methylpiperidin-1-yl)-5-(2,3-dichlorophenyl)-N-(2-hydroxyethyl)pyrimidine-4-carboxamide Chemical compound OCCNC(=O)C1=NC(=NC(=C1C1=C(C(=CC=C1)Cl)Cl)N)N1CCC(CC1)(C)N IWMGAWPGQYIEED-UHFFFAOYSA-N 0.000 claims description 2
- SXUPCARBIWILQE-UHFFFAOYSA-N 6-amino-2-(4-amino-4-methylpiperidin-1-yl)-5-(2,3-dichlorophenyl)-N-methylpyrimidine-4-carboxamide Chemical compound CNC(=O)C1=NC(=NC(=C1C1=C(C(=CC=C1)Cl)Cl)N)N1CCC(CC1)(C)N SXUPCARBIWILQE-UHFFFAOYSA-N 0.000 claims description 2
- ONKAWTQARQHIQO-UHFFFAOYSA-N 6-amino-2-(4-amino-4-methylpiperidin-1-yl)-5-(3-fluorophenyl)pyrimidine-4-carboxamide Chemical compound NC1=C(C(=NC(=N1)N1CCC(CC1)(C)N)C(=O)N)C1=CC(=CC=C1)F ONKAWTQARQHIQO-UHFFFAOYSA-N 0.000 claims description 2
- 229960003852 atezolizumab Drugs 0.000 claims description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 2
- 229950009791 durvalumab Drugs 0.000 claims description 2
- 229960003301 nivolumab Drugs 0.000 claims description 2
- 229960002621 pembrolizumab Drugs 0.000 claims description 2
- 206010038933 Retinopathy of prematurity Diseases 0.000 claims 3
- KZKRRZFCAYOXQE-UHFFFAOYSA-N 1$l^{2}-azinane Chemical group C1CC[N]CC1 KZKRRZFCAYOXQE-UHFFFAOYSA-N 0.000 claims 2
- KETZUNJWEVGBTA-UHFFFAOYSA-N 5-(2,3-dichlorophenyl)-6-methyl-2-(2-methyl-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrol-5-yl)pyrimidine-4-carboxamide Chemical compound ClC1=C(C=CC=C1Cl)C=1C(=NC(=NC=1C)N1CC2CN(CC2C1)C)C(=O)N KETZUNJWEVGBTA-UHFFFAOYSA-N 0.000 claims 2
- AURKNQJDGSCBLL-SFHVURJKSA-N 6-amino-2-[(4S)-4-amino-4-methylazepan-1-yl]-5-(2,3-dichlorophenyl)pyrimidine-4-carboxamide Chemical compound C[C@]1(N)CCCN(CC1)C1=NC(N)=C(C(=N1)C(N)=O)C1=C(Cl)C(Cl)=CC=C1 AURKNQJDGSCBLL-SFHVURJKSA-N 0.000 claims 2
- 208000032612 Glial tumor Diseases 0.000 claims 2
- 206010018338 Glioma Diseases 0.000 claims 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 claims 2
- 208000009905 Neurofibromatoses Diseases 0.000 claims 2
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 2
- 230000000112 colonic effect Effects 0.000 claims 2
- 201000004931 neurofibromatosis Diseases 0.000 claims 2
- 208000030266 primary brain neoplasm Diseases 0.000 claims 2
- 206010038038 rectal cancer Diseases 0.000 claims 2
- 201000001275 rectum cancer Diseases 0.000 claims 2
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 claims 1
- AWBOSXFRPFZLOP-UHFFFAOYSA-N 2,1,3-benzoxadiazole Chemical compound C1=CC=CC2=NON=C21 AWBOSXFRPFZLOP-UHFFFAOYSA-N 0.000 claims 1
- UZBGMFWCZBXQJJ-UHFFFAOYSA-N 2-(2-amino-5-azaspiro[2.4]heptan-5-yl)-5-(2,3-dichlorophenyl)-6-methylpyrimidine-4-carboxamide Chemical compound NC1CC11CN(CC1)C1=NC(=C(C(=N1)C(=O)N)C1=C(C(=CC=C1)Cl)Cl)C UZBGMFWCZBXQJJ-UHFFFAOYSA-N 0.000 claims 1
- OUYSDJPZZMDODU-UHFFFAOYSA-N 2-(3,9-diazabicyclo[4.2.1]nonan-3-yl)-5-(2,3-dichlorophenyl)-6-methylpyrimidine-4-carboxamide Chemical compound C12CN(CCC(CC1)N2)C1=NC(=C(C(=N1)C(=O)N)C1=C(C(=CC=C1)Cl)Cl)C OUYSDJPZZMDODU-UHFFFAOYSA-N 0.000 claims 1
- XMQNXELEDVGMDM-UHFFFAOYSA-N 2-(4-amino-3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrol-2-yl)-5-(2,3-dichlorophenyl)-6-methylpyrimidine-4-carboxamide hydrochloride Chemical compound Cl.NC1CCC2CN(CC21)C2=NC(=C(C(=N2)C(=O)N)C2=C(C(=CC=C2)Cl)Cl)C XMQNXELEDVGMDM-UHFFFAOYSA-N 0.000 claims 1
- NMZXLTJREWPHKA-UHFFFAOYSA-N 2-(4-amino-4-methylazepan-1-yl)-5-(2,3-dichlorophenyl)-6-methylpyrimidine-4-carboxamide Chemical compound NC1(CCN(CCC1)C1=NC(=C(C(=N1)C(=O)N)C1=C(C(=CC=C1)Cl)Cl)C)C NMZXLTJREWPHKA-UHFFFAOYSA-N 0.000 claims 1
- ZXWYKJJLZBOTIB-UHFFFAOYSA-N 2-(4-amino-4-methylpiperidin-1-yl)-5-(1H-benzimidazol-4-yl)pyrimidine-4-carboxamide Chemical compound NC1(CCN(CC1)C1=NC=C(C(=N1)C(=O)N)C1=CC=CC=2NC=NC=21)C ZXWYKJJLZBOTIB-UHFFFAOYSA-N 0.000 claims 1
- FGSAEVFUPCMPPL-UHFFFAOYSA-N 2-(4-amino-4-methylpiperidin-1-yl)-5-(1H-indol-3-yl)-6-methylpyrimidine-4-carboxamide Chemical compound NC1(CCN(CC1)C1=NC(=C(C(=N1)C(=O)N)C1=CNC2=CC=CC=C12)C)C FGSAEVFUPCMPPL-UHFFFAOYSA-N 0.000 claims 1
- VYKGJQCWJHETHC-UHFFFAOYSA-N 2-(4-amino-4-methylpiperidin-1-yl)-5-(2,1,3-benzoxadiazol-4-yl)pyrimidine-4-carboxamide Chemical compound NC1(CCN(CC1)C1=NC=C(C(=N1)C(=O)N)C1=CC=CC=2C1=NON=2)C VYKGJQCWJHETHC-UHFFFAOYSA-N 0.000 claims 1
- HUMIECSLNOZHDL-UHFFFAOYSA-N 2-(4-amino-4-methylpiperidin-1-yl)-5-(2,3-dichloropyridin-4-yl)-6-methylpyrimidine-4-carboxamide Chemical compound NC1(CCN(CC1)C1=NC(=C(C(=N1)C(=O)N)C1=C(C(=NC=C1)Cl)Cl)C)C HUMIECSLNOZHDL-UHFFFAOYSA-N 0.000 claims 1
- JDJOYVZXUUSEHT-UHFFFAOYSA-N 2-(4-amino-4-methylpiperidin-1-yl)-5-(2-chloro-4-fluorophenyl)-6-methylpyrimidine-4-carboxamide Chemical compound NC1(CCN(CC1)C1=NC(=C(C(=N1)C(=O)N)C1=C(C=C(C=C1)F)Cl)C)C JDJOYVZXUUSEHT-UHFFFAOYSA-N 0.000 claims 1
- LZBVVUCORWBSCZ-UHFFFAOYSA-N 2-(4-amino-4-methylpiperidin-1-yl)-5-(3-fluorophenyl)-6-oxo-1H-pyrimidine-4-carboxamide Chemical compound NC1(CCN(CC1)C1=NC(=C(C(=N1)C(=O)N)C1=CC(=CC=C1)F)O)C LZBVVUCORWBSCZ-UHFFFAOYSA-N 0.000 claims 1
- OYJDNTZCQICHOO-UHFFFAOYSA-N 2-(4-amino-4-methylpiperidin-1-yl)-5-(4-chloropyridin-3-yl)-6-methylpyrimidine-4-carboxamide Chemical compound NC1(CCN(CC1)C1=NC(=C(C(=N1)C(=O)N)C=1C=NC=CC=1Cl)C)C OYJDNTZCQICHOO-UHFFFAOYSA-N 0.000 claims 1
- STCLIZYTGXCNDU-UHFFFAOYSA-N 2-(4-amino-4-methylpiperidin-1-yl)-5-[2-chloro-3-(trifluoromethyl)phenyl]-6-methylpyrimidine-4-carboxamide Chemical compound NC1(CCN(CC1)C1=NC(=C(C(=N1)C(=O)N)C1=C(C(=CC=C1)C(F)(F)F)Cl)C)C STCLIZYTGXCNDU-UHFFFAOYSA-N 0.000 claims 1
- JPKBBCKCIKJDQT-UHFFFAOYSA-N 2-(4-amino-4-methylpiperidin-1-yl)-6-methyl-5-pyridin-4-ylpyrimidine-4-carboxamide Chemical compound NC1(CCN(CC1)C1=NC(=C(C(=N1)C(=O)N)C1=CC=NC=C1)C)C JPKBBCKCIKJDQT-UHFFFAOYSA-N 0.000 claims 1
- IZIJKPWQUPMEEQ-UHFFFAOYSA-N 2-(7-amino-3-oxa-9-azabicyclo[3.3.1]nonan-9-yl)-5-(2,3-dichlorophenyl)-6-methylpyrimidine-4-carboxamide Chemical compound NC1CC2COCC(C1)N2C1=NC(=C(C(=N1)C(=O)N)C1=C(C(=CC=C1)Cl)Cl)C IZIJKPWQUPMEEQ-UHFFFAOYSA-N 0.000 claims 1
- QIPGUJJZESIZDZ-UHFFFAOYSA-N 2-[(3-aminocyclohexyl)amino]-5-(2,3-dichlorophenyl)-6-methylpyrimidine-4-carboxamide Chemical compound NC1CC(CCC1)NC1=NC(=C(C(=N1)C(=O)N)C1=C(C(=CC=C1)Cl)Cl)C QIPGUJJZESIZDZ-UHFFFAOYSA-N 0.000 claims 1
- BLCIDIAYQMYEOC-OAQYLSRUSA-N 2-[(3R)-3-aminospiro[3H-1-benzofuran-2,4'-piperidine]-1'-yl]-5-(2,3-dichlorophenyl)-6-methylpyrimidine-4-carboxamide Chemical compound N[C@@H]1C2=C(OC11CCN(CC1)C1=NC(=C(C(=N1)C(=O)N)C1=C(C(=CC=C1)Cl)Cl)C)C=CC=C2 BLCIDIAYQMYEOC-OAQYLSRUSA-N 0.000 claims 1
- HTHQAPAUUPTFGS-MNOVXSKESA-N 2-[(3R,4S)-3-amino-4-hydroxypyrrolidin-1-yl]-5-(2,3-dichlorophenyl)-6-methylpyrimidine-4-carboxamide Chemical compound N[C@@H]1CN(C[C@@H]1O)C1=NC(=C(C(=N1)C(=O)N)C1=C(C(=CC=C1)Cl)Cl)C HTHQAPAUUPTFGS-MNOVXSKESA-N 0.000 claims 1
- HTHQAPAUUPTFGS-QWRGUYRKSA-N 2-[(3S,4S)-3-amino-4-hydroxypyrrolidin-1-yl]-5-(2,3-dichlorophenyl)-6-methylpyrimidine-4-carboxamide Chemical compound N[C@H]1CN(C[C@@H]1O)C1=NC(=C(C(=N1)C(=O)N)C1=C(C(=CC=C1)Cl)Cl)C HTHQAPAUUPTFGS-QWRGUYRKSA-N 0.000 claims 1
- RMQMWZYNKFDZCH-RJXBTYEGSA-N 2-[(3aR,6aR)-4-amino-3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrol-2-yl]-5-(2,3-dichlorophenyl)-6-methylpyrimidine-4-carboxamide Chemical compound NC1CC[C@H]2CN(C[C@@H]21)C1=NC(=C(C(=N1)C(=O)N)C1=C(C(=CC=C1)Cl)Cl)C RMQMWZYNKFDZCH-RJXBTYEGSA-N 0.000 claims 1
- RMQMWZYNKFDZCH-ZKYQVNSYSA-N 2-[(3aS,4R,6aR)-4-amino-3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrol-2-yl]-5-(2,3-dichlorophenyl)-6-methylpyrimidine-4-carboxamide Chemical compound N[C@@H]1CC[C@H]2CN(C[C@H]21)C1=NC(=C(C(=N1)C(=O)N)C1=C(C(=CC=C1)Cl)Cl)C RMQMWZYNKFDZCH-ZKYQVNSYSA-N 0.000 claims 1
- RMQMWZYNKFDZCH-RMPUTMTLSA-N 2-[(3aS,6aS)-4-amino-3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrol-2-yl]-5-(2,3-dichlorophenyl)-6-methylpyrimidine-4-carboxamide Chemical compound NC1CC[C@@H]2CN(C[C@H]21)C1=NC(=C(C(=N1)C(=O)N)C1=C(C(=CC=C1)Cl)Cl)C RMQMWZYNKFDZCH-RMPUTMTLSA-N 0.000 claims 1
- RLQBENSEHAWHSH-UHFFFAOYSA-N 2-[(4-aminocyclohexyl)amino]-5-(2,3-dichlorophenyl)-6-methylpyrimidine-4-carboxamide Chemical compound NC1CCC(CC1)NC1=NC(=C(C(=N1)C(=O)N)C1=C(C(=CC=C1)Cl)Cl)C RLQBENSEHAWHSH-UHFFFAOYSA-N 0.000 claims 1
- AZIVYVCMTYVJJH-QMRFKDRMSA-N 2-[(9R)-9-amino-2-azaspiro[4.4]nonan-2-yl]-5-(2,3-dichlorophenyl)-6-methylpyrimidine-4-carboxamide Chemical compound CC1=NC(=NC(C(N)=O)=C1C1=C(Cl)C(Cl)=CC=C1)N1CCC2(CCC[C@H]2N)C1 AZIVYVCMTYVJJH-QMRFKDRMSA-N 0.000 claims 1
- AZIVYVCMTYVJJH-PVCZSOGJSA-N 2-[(9S)-9-amino-2-azaspiro[4.4]nonan-2-yl]-5-(2,3-dichlorophenyl)-6-methylpyrimidine-4-carboxamide Chemical compound CC1=NC(=NC(C(N)=O)=C1C1=C(Cl)C(Cl)=CC=C1)N1CCC2(CCC[C@@H]2N)C1 AZIVYVCMTYVJJH-PVCZSOGJSA-N 0.000 claims 1
- KQRBBJFLHPSKTF-UHFFFAOYSA-N 2-[2-(aminomethyl)azetidin-1-yl]-5-(2,3-dichlorophenyl)-6-methylpyrimidine-4-carboxamide Chemical compound NCC1N(CC1)C1=NC(=C(C(=N1)C(=O)N)C1=C(C(=CC=C1)Cl)Cl)C KQRBBJFLHPSKTF-UHFFFAOYSA-N 0.000 claims 1
- PKLYMCZBLNEYNY-UHFFFAOYSA-N 2-[3-(aminomethyl)-3-fluoroazetidin-1-yl]-5-(2,3-dichlorophenyl)-6-methylpyrimidine-4-carboxamide Chemical compound NCC1(CN(C1)C1=NC(=C(C(=N1)C(=O)N)C1=C(C(=CC=C1)Cl)Cl)C)F PKLYMCZBLNEYNY-UHFFFAOYSA-N 0.000 claims 1
- VNEBEQOBOXTEDK-UHFFFAOYSA-N 2-[3-amino-3-(hydroxymethyl)azetidin-1-yl]-5-(2,3-dichlorophenyl)-6-methylpyrimidine-4-carboxamide Chemical compound NC1(CN(C1)C1=NC(=C(C(=N1)C(=O)N)C1=C(C(=CC=C1)Cl)Cl)C)CO VNEBEQOBOXTEDK-UHFFFAOYSA-N 0.000 claims 1
- QIPGUJJZESIZDZ-WDEREUQCSA-N 2-[[(1R,3S)-3-aminocyclohexyl]amino]-5-(2,3-dichlorophenyl)-6-methylpyrimidine-4-carboxamide Chemical compound CC1=NC(N[C@@H]2CCC[C@H](N)C2)=NC(C(N)=O)=C1C1=C(Cl)C(Cl)=CC=C1 QIPGUJJZESIZDZ-WDEREUQCSA-N 0.000 claims 1
- QIPGUJJZESIZDZ-MNOVXSKESA-N 2-[[(1S,3R)-3-aminocyclohexyl]amino]-5-(2,3-dichlorophenyl)-6-methylpyrimidine-4-carboxamide Chemical compound CC1=NC(N[C@H]2CCC[C@@H](N)C2)=NC(C(N)=O)=C1C1=C(Cl)C(Cl)=CC=C1 QIPGUJJZESIZDZ-MNOVXSKESA-N 0.000 claims 1
- KTHIVOHQSNLLMB-UHFFFAOYSA-N 2-[[2-(aminomethyl)cyclopentyl]amino]-5-(2,3-dichlorophenyl)-6-methylpyrimidine-4-carboxamide Chemical compound NCC1C(CCC1)NC1=NC(=C(C(=N1)C(=O)N)C1=C(C(=CC=C1)Cl)Cl)C KTHIVOHQSNLLMB-UHFFFAOYSA-N 0.000 claims 1
- QBWQXMJNXUQART-UHFFFAOYSA-N 2-[[3-(aminomethyl)cyclopentyl]amino]-5-(2,3-dichlorophenyl)-6-methylpyrimidine-4-carboxamide Chemical compound NCC1CC(CC1)NC1=NC(=C(C(=N1)C(=O)N)C1=C(C(=CC=C1)Cl)Cl)C QBWQXMJNXUQART-UHFFFAOYSA-N 0.000 claims 1
- WRWZXZNHYGVRFP-UHFFFAOYSA-N 2-methylpyrimidine-4-carboxamide Chemical compound CC1=NC=CC(C(N)=O)=N1 WRWZXZNHYGVRFP-UHFFFAOYSA-N 0.000 claims 1
- ZIBGSXLCGSPZTE-UHFFFAOYSA-N 6-[(4-aminocyclohexyl)-methylamino]-3-(2,3-dichlorophenyl)-2-methylpyridine-4-carboxamide Chemical compound CN(C1CCC(N)CC1)C1=CC(C(N)=O)=C(C(C)=N1)C1=C(Cl)C(Cl)=CC=C1 ZIBGSXLCGSPZTE-UHFFFAOYSA-N 0.000 claims 1
- PLBHBJFAVDOPEH-UHFFFAOYSA-N 6-amino-2-(3-aminoazetidin-1-yl)-5-(2,3-dichlorophenyl)pyrimidine-4-carboxamide Chemical compound NC1=C(C(=NC(=N1)N1CC(C1)N)C(=O)N)C1=C(C(=CC=C1)Cl)Cl PLBHBJFAVDOPEH-UHFFFAOYSA-N 0.000 claims 1
- SOVQPROKSCVFRZ-UHFFFAOYSA-N 6-amino-2-(4-aminoazepan-1-yl)-5-(2,3-dichlorophenyl)pyrimidine-4-carboxamide Chemical compound NC1=C(C(=NC(=N1)N1CCC(CCC1)N)C(=O)N)C1=C(C(=CC=C1)Cl)Cl SOVQPROKSCVFRZ-UHFFFAOYSA-N 0.000 claims 1
- CJJBPECAZYUJHQ-UHFFFAOYSA-N 6-amino-2-[(4-aminocyclohexyl)-methylamino]-5-(2,3-dichlorophenyl)pyrimidine-4-carboxamide Chemical compound NC1=C(C(=NC(=N1)N(C)C1CCC(CC1)N)C(=O)N)C1=C(C(=CC=C1)Cl)Cl CJJBPECAZYUJHQ-UHFFFAOYSA-N 0.000 claims 1
- AURKNQJDGSCBLL-GOSISDBHSA-N 6-amino-2-[(4R)-4-amino-4-methylazepan-1-yl]-5-(2,3-dichlorophenyl)pyrimidine-4-carboxamide Chemical compound C[C@@]1(N)CCCN(CC1)C1=NC(N)=C(C(=N1)C(N)=O)C1=C(Cl)C(Cl)=CC=C1 AURKNQJDGSCBLL-GOSISDBHSA-N 0.000 claims 1
- IXHRRMHBQMVAQH-UHFFFAOYSA-N 6-amino-2-[3-(aminomethyl)-3-hydroxyazetidin-1-yl]-5-(2,3-dichlorophenyl)pyrimidine-4-carboxamide Chemical compound NC1=C(C(=NC(=N1)N1CC(C1)(O)CN)C(=O)N)C1=C(C(=CC=C1)Cl)Cl IXHRRMHBQMVAQH-UHFFFAOYSA-N 0.000 claims 1
- NGIUTQIZUNYKTH-UHFFFAOYSA-N 6-amino-2-[3-(aminomethyl)-3-methylazetidin-1-yl]-5-(2,3-dichlorophenyl)pyrimidine-4-carboxamide Chemical compound NC1=C(C(=NC(=N1)N1CC(C1)(C)CN)C(=O)N)C1=C(C(=CC=C1)Cl)Cl NGIUTQIZUNYKTH-UHFFFAOYSA-N 0.000 claims 1
- INZXPGARNZVJIM-UHFFFAOYSA-N 6-amino-2-[4-(aminomethyl)-4-methylpiperidin-1-yl]-5-(2,3-dichlorophenyl)pyrimidine-4-carboxamide Chemical compound NC1=C(C(=NC(=N1)N1CCC(CC1)(C)CN)C(=O)N)C1=C(C(=CC=C1)Cl)Cl INZXPGARNZVJIM-UHFFFAOYSA-N 0.000 claims 1
- HZYYDNYGLLCFHE-WDEREUQCSA-N 6-amino-2-[[(1R,2S)-2-aminocyclohexyl]amino]-5-(2,3-dichlorophenyl)pyrimidine-4-carboxamide Chemical compound NC1=C(C(=NC(=N1)N[C@H]1[C@H](CCCC1)N)C(=O)N)C1=C(C(=CC=C1)Cl)Cl HZYYDNYGLLCFHE-WDEREUQCSA-N 0.000 claims 1
- 206010061692 Benign muscle neoplasm Diseases 0.000 claims 1
- 201000004458 Myoma Diseases 0.000 claims 1
- 229940121420 cemiplimab Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 claims 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 claims 1
- 150000003053 piperidines Chemical group 0.000 claims 1
- 125000003386 piperidinyl group Chemical group 0.000 claims 1
- 206010041823 squamous cell carcinoma Diseases 0.000 claims 1
- 230000003463 hyperproliferative effect Effects 0.000 abstract description 10
- 208000037765 diseases and disorders Diseases 0.000 abstract description 5
- 241000124008 Mammalia Species 0.000 abstract description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 189
- 238000004811 liquid chromatography Methods 0.000 description 124
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 116
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 111
- 239000007787 solid Substances 0.000 description 109
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 98
- 239000000203 mixture Substances 0.000 description 98
- 239000000243 solution Substances 0.000 description 96
- 235000019439 ethyl acetate Nutrition 0.000 description 92
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 90
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 70
- 238000005160 1H NMR spectroscopy Methods 0.000 description 66
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 60
- 239000000543 intermediate Substances 0.000 description 59
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 54
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 49
- 238000003818 flash chromatography Methods 0.000 description 46
- 239000000377 silicon dioxide Substances 0.000 description 44
- 239000012044 organic layer Substances 0.000 description 42
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 39
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 36
- 239000011541 reaction mixture Substances 0.000 description 35
- 230000002829 reductive effect Effects 0.000 description 34
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 33
- 239000002904 solvent Substances 0.000 description 33
- 238000000746 purification Methods 0.000 description 32
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 31
- 238000010828 elution Methods 0.000 description 30
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 27
- 238000006243 chemical reaction Methods 0.000 description 26
- 239000000825 pharmaceutical preparation Substances 0.000 description 25
- 239000012267 brine Substances 0.000 description 24
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 24
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 22
- 229910052938 sodium sulfate Inorganic materials 0.000 description 21
- 235000011152 sodium sulphate Nutrition 0.000 description 21
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 20
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 20
- 230000000694 effects Effects 0.000 description 19
- 238000002953 preparative HPLC Methods 0.000 description 19
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 18
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 17
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 16
- FUFZNHHSSMCXCZ-UHFFFAOYSA-N 5-piperidin-4-yl-3-[3-(trifluoromethyl)phenyl]-1,2,4-oxadiazole Chemical compound FC(F)(F)C1=CC=CC(C=2N=C(ON=2)C2CCNCC2)=C1 FUFZNHHSSMCXCZ-UHFFFAOYSA-N 0.000 description 16
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 16
- 229940079593 drug Drugs 0.000 description 15
- 239000000843 powder Substances 0.000 description 15
- 238000002360 preparation method Methods 0.000 description 15
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 14
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 14
- LGDIQVXVHPZOKR-UHFFFAOYSA-N 6-amino-5-(2,3-dichlorophenyl)-2-methylsulfonylpyrimidine-4-carbonitrile Chemical compound NC1=C(C(=NC(=N1)S(=O)(=O)C)C#N)C1=C(C(=CC=C1)Cl)Cl LGDIQVXVHPZOKR-UHFFFAOYSA-N 0.000 description 12
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 12
- 238000005481 NMR spectroscopy Methods 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 12
- 239000000706 filtrate Substances 0.000 description 12
- 239000012299 nitrogen atmosphere Substances 0.000 description 12
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 12
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 12
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 11
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 11
- 238000013459 approach Methods 0.000 description 11
- QGDKXBHGXOBNSW-UHFFFAOYSA-N spiro[1-benzofuran-2,4'-piperidine]-3-one Chemical compound O=C1C2=CC=CC=C2OC11CCNCC1 QGDKXBHGXOBNSW-UHFFFAOYSA-N 0.000 description 11
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 10
- 239000013058 crude material Substances 0.000 description 10
- 125000000753 cycloalkyl group Chemical group 0.000 description 10
- 125000006239 protecting group Chemical group 0.000 description 10
- 239000011734 sodium Substances 0.000 description 10
- 239000007858 starting material Substances 0.000 description 10
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- 239000000460 chlorine Substances 0.000 description 9
- 239000006260 foam Substances 0.000 description 9
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 9
- 229940127557 pharmaceutical product Drugs 0.000 description 9
- 230000004962 physiological condition Effects 0.000 description 9
- 238000000926 separation method Methods 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- YGUFCDOEKKVKJK-UHFFFAOYSA-N 6-(4-amino-4-methylpiperidin-1-yl)-3-(2,3-dichlorophenyl)pyrazin-2-amine Chemical compound NC1(CCN(CC1)C1=CN=C(C(=N1)N)C1=C(C(=CC=C1)Cl)Cl)C YGUFCDOEKKVKJK-UHFFFAOYSA-N 0.000 description 8
- 150000002081 enamines Chemical class 0.000 description 8
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 8
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 8
- 230000004963 pathophysiological condition Effects 0.000 description 8
- 230000008569 process Effects 0.000 description 8
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 description 8
- 239000012453 solvate Substances 0.000 description 8
- TYIKXPOMOYDGCS-UHFFFAOYSA-N (2,3-dichlorophenyl)boronic acid Chemical compound OB(O)C1=CC=CC(Cl)=C1Cl TYIKXPOMOYDGCS-UHFFFAOYSA-N 0.000 description 7
- 102000004127 Cytokines Human genes 0.000 description 7
- 239000002246 antineoplastic agent Substances 0.000 description 7
- 125000004429 atom Chemical group 0.000 description 7
- 238000001035 drying Methods 0.000 description 7
- 239000003102 growth factor Substances 0.000 description 7
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 7
- 235000019341 magnesium sulphate Nutrition 0.000 description 7
- 229910052757 nitrogen Inorganic materials 0.000 description 7
- 229940083082 pyrimidine derivative acting on arteriolar smooth muscle Drugs 0.000 description 7
- 229920006395 saturated elastomer Polymers 0.000 description 7
- 230000019491 signal transduction Effects 0.000 description 7
- 238000002560 therapeutic procedure Methods 0.000 description 7
- SDYFYBAYSDNFRP-UHFFFAOYSA-N 2-chloro-6-methylpyrimidine-4-carbonitrile Chemical compound CC1=CC(C#N)=NC(Cl)=N1 SDYFYBAYSDNFRP-UHFFFAOYSA-N 0.000 description 6
- 108090000695 Cytokines Proteins 0.000 description 6
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 6
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 6
- 230000004913 activation Effects 0.000 description 6
- 125000002252 acyl group Chemical group 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 239000012298 atmosphere Substances 0.000 description 6
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 6
- 230000035772 mutation Effects 0.000 description 6
- 229960005419 nitrogen Drugs 0.000 description 6
- 229910000027 potassium carbonate Inorganic materials 0.000 description 6
- 108090000765 processed proteins & peptides Proteins 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- ZIEWSZYVEDTXGH-UHFFFAOYSA-N pyrimidine-4-carbonitrile Chemical compound N#CC1=CC=NC=N1 ZIEWSZYVEDTXGH-UHFFFAOYSA-N 0.000 description 6
- 239000000741 silica gel Substances 0.000 description 6
- 229910002027 silica gel Inorganic materials 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- PQOKJQKPHJSIME-UHFFFAOYSA-N CC(C)(C)N(C(O)=O)C1(C)CCNCC1 Chemical compound CC(C)(C)N(C(O)=O)C1(C)CCNCC1 PQOKJQKPHJSIME-UHFFFAOYSA-N 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 229940125999 RMC-4550 Drugs 0.000 description 5
- IKUYEYLZXGGCRD-ORAYPTAESA-N [3-[(3S,4S)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-6-(2,3-dichlorophenyl)-5-methylpyrazin-2-yl]methanol Chemical compound N[C@@H]1[C@@H](OCC11CCN(CC1)C=1C(=NC(=C(N=1)C)C1=C(C(=CC=C1)Cl)Cl)CO)C IKUYEYLZXGGCRD-ORAYPTAESA-N 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 150000003857 carboxamides Chemical class 0.000 description 5
- 229910052739 hydrogen Inorganic materials 0.000 description 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 239000010410 layer Substances 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 235000019198 oils Nutrition 0.000 description 5
- 230000002265 prevention Effects 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 230000004083 survival effect Effects 0.000 description 5
- 206010048610 Cardiotoxicity Diseases 0.000 description 4
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 4
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 4
- 108090000862 Ion Channels Proteins 0.000 description 4
- 102000004310 Ion Channels Human genes 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 102100028516 Receptor-type tyrosine-protein phosphatase U Human genes 0.000 description 4
- 230000001594 aberrant effect Effects 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 4
- 150000001412 amines Chemical class 0.000 description 4
- 125000003277 amino group Chemical group 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 231100000259 cardiotoxicity Toxicity 0.000 description 4
- 230000004663 cell proliferation Effects 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 229910052801 chlorine Inorganic materials 0.000 description 4
- 238000006880 cross-coupling reaction Methods 0.000 description 4
- 229910052805 deuterium Inorganic materials 0.000 description 4
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 4
- 229910052731 fluorine Inorganic materials 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 239000001257 hydrogen Substances 0.000 description 4
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- KCXFHTAICRTXLI-UHFFFAOYSA-N propane-1-sulfonic acid Chemical compound CCCS(O)(=O)=O KCXFHTAICRTXLI-UHFFFAOYSA-N 0.000 description 4
- LFILDSDQMSCNBV-LURJTMIESA-N propane-2-sulfinamide Chemical compound CC(C)[S@@](N)=O LFILDSDQMSCNBV-LURJTMIESA-N 0.000 description 4
- 150000003230 pyrimidines Chemical class 0.000 description 4
- 229910052717 sulfur Inorganic materials 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- UGOMMVLRQDMAQQ-UHFFFAOYSA-N xphos Chemical compound CC(C)C1=CC(C(C)C)=CC(C(C)C)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 UGOMMVLRQDMAQQ-UHFFFAOYSA-N 0.000 description 4
- CESUXLKAADQNTB-SSDOTTSWSA-N 2-methylpropane-2-sulfinamide Chemical compound CC(C)(C)[S@](N)=O CESUXLKAADQNTB-SSDOTTSWSA-N 0.000 description 3
- JMTMSDXUXJISAY-UHFFFAOYSA-N 2H-benzotriazol-4-ol Chemical compound OC1=CC=CC2=C1N=NN2 JMTMSDXUXJISAY-UHFFFAOYSA-N 0.000 description 3
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 3
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 3
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 3
- 108010032107 Non-Receptor Type 11 Protein Tyrosine Phosphatase Proteins 0.000 description 3
- 102000007607 Non-Receptor Type 11 Protein Tyrosine Phosphatase Human genes 0.000 description 3
- 101150048674 PTPN11 gene Proteins 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 150000001408 amides Chemical class 0.000 description 3
- 239000000908 ammonium hydroxide Substances 0.000 description 3
- 239000003708 ampul Substances 0.000 description 3
- 230000000692 anti-sense effect Effects 0.000 description 3
- 239000004305 biphenyl Substances 0.000 description 3
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 3
- 229910000024 caesium carbonate Inorganic materials 0.000 description 3
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 125000005842 heteroatom Chemical group 0.000 description 3
- 150000002430 hydrocarbons Chemical group 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 125000001841 imino group Chemical group [H]N=* 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 3
- 230000002503 metabolic effect Effects 0.000 description 3
- 239000002207 metabolite Substances 0.000 description 3
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 229940002612 prodrug Drugs 0.000 description 3
- 239000000651 prodrug Substances 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 125000004076 pyridyl group Chemical group 0.000 description 3
- 239000000376 reactant Substances 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 239000011347 resin Substances 0.000 description 3
- 229920005989 resin Polymers 0.000 description 3
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 230000011664 signaling Effects 0.000 description 3
- PODWXQQNRWNDGD-UHFFFAOYSA-L sodium thiosulfate pentahydrate Chemical compound O.O.O.O.O.[Na+].[Na+].[O-]S([S-])(=O)=O PODWXQQNRWNDGD-UHFFFAOYSA-L 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 3
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 3
- HVWNCMUDCXXJSA-UHFFFAOYSA-N (2-fluorophenyl)-(4-hydroxypiperidin-4-yl)methanone Chemical compound C=1C=CC=C(F)C=1C(=O)C1(O)CCNCC1 HVWNCMUDCXXJSA-UHFFFAOYSA-N 0.000 description 2
- KNXQDJCZSVHEIW-UHFFFAOYSA-N (3-fluorophenyl)boronic acid Chemical compound OB(O)C1=CC=CC(F)=C1 KNXQDJCZSVHEIW-UHFFFAOYSA-N 0.000 description 2
- TZJWHSMOBCULEZ-RFVHGSKJSA-N (3R)-spiro[3H-1-benzofuran-2,4'-piperidine]-3-amine hydrochloride Chemical compound Cl.N1CCC2(CC1)OC1=C([C@H]2N)C=CC=C1 TZJWHSMOBCULEZ-RFVHGSKJSA-N 0.000 description 2
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 description 2
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 2
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 2
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 2
- LOZWAPSEEHRYPG-UHFFFAOYSA-N 1,4-dithiane Chemical compound C1CSCCS1 LOZWAPSEEHRYPG-UHFFFAOYSA-N 0.000 description 2
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 2
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Chemical compound C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 2
- HBEDSQVIWPRPAY-UHFFFAOYSA-N 2,3-dihydrobenzofuran Chemical compound C1=CC=C2OCCC2=C1 HBEDSQVIWPRPAY-UHFFFAOYSA-N 0.000 description 2
- NSBGJIWOKGWANC-UHFFFAOYSA-N 2-(2-fluorophenyl)-1,3-dithiane Chemical compound FC1=CC=CC=C1C1SCCCS1 NSBGJIWOKGWANC-UHFFFAOYSA-N 0.000 description 2
- BLCIDIAYQMYEOC-NRFANRHFSA-N 2-[(3S)-3-aminospiro[3H-1-benzofuran-2,4'-piperidine]-1'-yl]-5-(2,3-dichlorophenyl)-6-methylpyrimidine-4-carboxamide Chemical compound N[C@H]1C2=C(OC11CCN(CC1)C1=NC(=C(C(=N1)C(=O)N)C1=C(C(=CC=C1)Cl)Cl)C)C=CC=C2 BLCIDIAYQMYEOC-NRFANRHFSA-N 0.000 description 2
- ZZFMYBMLMRYHML-UHFFFAOYSA-N 3-(1,3-dithian-2-yl)-2-fluoropyridine Chemical compound S1C(SCCC1)C=1C(=NC=CC=1)F ZZFMYBMLMRYHML-UHFFFAOYSA-N 0.000 description 2
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 description 2
- DZANYXOTJVLAEE-UHFFFAOYSA-N 6,8-difluoro-4-methylumbelliferyl phosphate Chemical compound FC1=C(OP(O)(O)=O)C(F)=CC2=C1OC(=O)C=C2C DZANYXOTJVLAEE-UHFFFAOYSA-N 0.000 description 2
- DVUZWEAFTZGFFS-UHFFFAOYSA-N 6-amino-2-(4-amino-4-methylpiperidin-1-yl)-5-(2,3-dichlorophenyl)pyrimidine-4-carboxylic acid Chemical compound NC1=C(C(=NC(=N1)N1CCC(CC1)(C)N)C(=O)O)C1=C(C(=CC=C1)Cl)Cl DVUZWEAFTZGFFS-UHFFFAOYSA-N 0.000 description 2
- ZVBKQUJDZNBBGY-UHFFFAOYSA-N 6-amino-2-chloropyrimidine-4-carbonitrile Chemical compound NC1=CC(C#N)=NC(Cl)=N1 ZVBKQUJDZNBBGY-UHFFFAOYSA-N 0.000 description 2
- NIPXSXBQQYEFDI-UHFFFAOYSA-N 6-amino-2-methylsulfanylpyrimidine-4-carbonitrile Chemical compound CSc1nc(N)cc(n1)C#N NIPXSXBQQYEFDI-UHFFFAOYSA-N 0.000 description 2
- BDUDPQJFTROBRK-UHFFFAOYSA-N 6-amino-5-bromo-2-methylsulfanylpyrimidine-4-carbonitrile Chemical compound CSc1nc(N)c(Br)c(n1)C#N BDUDPQJFTROBRK-UHFFFAOYSA-N 0.000 description 2
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- 108010006654 Bleomycin Proteins 0.000 description 2
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 2
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 2
- 108010092160 Dactinomycin Proteins 0.000 description 2
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 2
- 238000012424 Freeze-thaw process Methods 0.000 description 2
- 108010009202 Growth Factor Receptors Proteins 0.000 description 2
- 239000007821 HATU Substances 0.000 description 2
- 101000610640 Homo sapiens U4/U6 small nuclear ribonucleoprotein Prp3 Proteins 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- 102000004889 Interleukin-6 Human genes 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 102000019149 MAP kinase activity proteins Human genes 0.000 description 2
- 108040008097 MAP kinase activity proteins Proteins 0.000 description 2
- 108091054455 MAP kinase family Proteins 0.000 description 2
- 102000043136 MAP kinase family Human genes 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- 208000033833 Myelomonocytic Chronic Leukemia Diseases 0.000 description 2
- 208000037538 Myelomonocytic Juvenile Leukemia Diseases 0.000 description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 101001110823 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) 60S ribosomal protein L6-A Proteins 0.000 description 2
- 101000712176 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) 60S ribosomal protein L6-B Proteins 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 2
- 102100040374 U4/U6 small nuclear ribonucleoprotein Prp3 Human genes 0.000 description 2
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 2
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 238000007605 air drying Methods 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- 229960002932 anastrozole Drugs 0.000 description 2
- YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 description 2
- 238000009175 antibody therapy Methods 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 125000003710 aryl alkyl group Chemical group 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 238000010256 biochemical assay Methods 0.000 description 2
- 235000010290 biphenyl Nutrition 0.000 description 2
- 229960001561 bleomycin Drugs 0.000 description 2
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 229960002092 busulfan Drugs 0.000 description 2
- 229940127093 camptothecin Drugs 0.000 description 2
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 2
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 description 2
- XNRHTMDHGDWBGP-UHFFFAOYSA-N carbamic acid;hydrochloride Chemical compound Cl.NC(O)=O XNRHTMDHGDWBGP-UHFFFAOYSA-N 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 229960005395 cetuximab Drugs 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 201000010902 chronic myelomonocytic leukemia Diseases 0.000 description 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 2
- 229960004316 cisplatin Drugs 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 229940126142 compound 16 Drugs 0.000 description 2
- 229940125782 compound 2 Drugs 0.000 description 2
- 229940125898 compound 5 Drugs 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 229960004397 cyclophosphamide Drugs 0.000 description 2
- 229960000640 dactinomycin Drugs 0.000 description 2
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 239000011903 deuterated solvents Substances 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 description 2
- 229960003668 docetaxel Drugs 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 2
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 229960002949 fluorouracil Drugs 0.000 description 2
- MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 2
- 229960002074 flutamide Drugs 0.000 description 2
- 210000002196 fr. b Anatomy 0.000 description 2
- 210000003918 fraction a Anatomy 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 2
- 229960005277 gemcitabine Drugs 0.000 description 2
- 238000010914 gene-directed enzyme pro-drug therapy Methods 0.000 description 2
- TZBJGXHYKVUXJN-UHFFFAOYSA-N genistein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O TZBJGXHYKVUXJN-UHFFFAOYSA-N 0.000 description 2
- 230000005283 ground state Effects 0.000 description 2
- 230000026030 halogenation Effects 0.000 description 2
- 238000005658 halogenation reaction Methods 0.000 description 2
- 229940022353 herceptin Drugs 0.000 description 2
- 125000004404 heteroalkyl group Chemical group 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 125000002883 imidazolyl group Chemical group 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 230000005445 isotope effect Effects 0.000 description 2
- 201000005992 juvenile myelomonocytic leukemia Diseases 0.000 description 2
- 229940043355 kinase inhibitor Drugs 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 2
- 230000023185 monocyte chemotactic protein-1 production Effects 0.000 description 2
- 125000001624 naphthyl group Chemical group 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- HXITXNWTGFUOAU-UHFFFAOYSA-N phenylboronic acid Chemical compound OB(O)C1=CC=CC=C1 HXITXNWTGFUOAU-UHFFFAOYSA-N 0.000 description 2
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 2
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 2
- LOUPRKONTZGTKE-LHHVKLHASA-N quinidine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@H]2[C@@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-LHHVKLHASA-N 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 102200155721 rs121918464 Human genes 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N serine Chemical compound OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- 239000012279 sodium borohydride Substances 0.000 description 2
- 229910000033 sodium borohydride Inorganic materials 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 125000003107 substituted aryl group Chemical group 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- YOBHKOFPTPECCM-UHFFFAOYSA-N tert-butyl 4-(2-fluoropyridine-3-carbonyl)-4-hydroxypiperidine-1-carboxylate Chemical compound FC1=NC=CC=C1C(=O)C1(CCN(CC1)C(=O)OC(C)(C)C)O YOBHKOFPTPECCM-UHFFFAOYSA-N 0.000 description 2
- ROUYFJUVMYHXFJ-UHFFFAOYSA-N tert-butyl 4-oxopiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(=O)CC1 ROUYFJUVMYHXFJ-UHFFFAOYSA-N 0.000 description 2
- HHFWMPHNJGBXIT-UHFFFAOYSA-N tert-butyl N-[1-[4-amino-6-carbamoyl-5-(3-chlorophenyl)pyrimidin-2-yl]-4-methylpiperidin-4-yl]carbamate Chemical compound NC1=NC(=NC(=C1C1=CC(=CC=C1)Cl)C(N)=O)N1CCC(CC1)(C)NC(OC(C)(C)C)=O HHFWMPHNJGBXIT-UHFFFAOYSA-N 0.000 description 2
- 125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- JRMUNVKIHCOMHV-UHFFFAOYSA-M tetrabutylammonium bromide Chemical compound [Br-].CCCC[N+](CCCC)(CCCC)CCCC JRMUNVKIHCOMHV-UHFFFAOYSA-M 0.000 description 2
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 2
- 125000001544 thienyl group Chemical group 0.000 description 2
- 125000004055 thiomethyl group Chemical group [H]SC([H])([H])* 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- BMKDZUISNHGIBY-ZETCQYMHSA-N (+)-dexrazoxane Chemical compound C([C@H](C)N1CC(=O)NC(=O)C1)N1CC(=O)NC(=O)C1 BMKDZUISNHGIBY-ZETCQYMHSA-N 0.000 description 1
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 1
- GLGNXYJARSMNGJ-VKTIVEEGSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-ethyl-6-methoxy-2-oxo-4,5-dihydro-3h-1-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound CCN1C(=O)CCCC2=C(OC)C(NC=3N=C(C(=CN=3)Cl)N[C@H]3[C@H]([C@@]4([H])C[C@@]3(C=C4)[H])C(N)=O)=CC=C21 GLGNXYJARSMNGJ-VKTIVEEGSA-N 0.000 description 1
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 1
- ITOFPJRDSCGOSA-KZLRUDJFSA-N (2s)-2-[[(4r)-4-[(3r,5r,8r,9s,10s,13r,14s,17r)-3-hydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]pentanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H](CC[C@]13C)[C@@H]2[C@@H]3CC[C@@H]1[C@H](C)CCC(=O)N[C@H](C(O)=O)CC1=CNC2=CC=CC=C12 ITOFPJRDSCGOSA-KZLRUDJFSA-N 0.000 description 1
- WWTBZEKOSBFBEM-SPWPXUSOSA-N (2s)-2-[[2-benzyl-3-[hydroxy-[(1r)-2-phenyl-1-(phenylmethoxycarbonylamino)ethyl]phosphoryl]propanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)O)C(=O)C(CP(O)(=O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1C=CC=CC=1)CC1=CC=CC=C1 WWTBZEKOSBFBEM-SPWPXUSOSA-N 0.000 description 1
- SDEAGACSNFSZCU-UHFFFAOYSA-N (3-chlorophenyl)boronic acid Chemical compound OB(O)C1=CC=CC(Cl)=C1 SDEAGACSNFSZCU-UHFFFAOYSA-N 0.000 description 1
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 1
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 1
- LQLBBHWJXRRCEU-SECBINFHSA-N (4S)-spiro[4,6-dihydrocyclopenta[d][1,3]thiazole-5,4'-piperidine]-4-amine Chemical compound N1CCC2(CC1)CC1=C(N=CS1)[C@H]2N LQLBBHWJXRRCEU-SECBINFHSA-N 0.000 description 1
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 description 1
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 1
- LKJPYSCBVHEWIU-KRWDZBQOSA-N (R)-bicalutamide Chemical compound C([C@@](O)(C)C(=O)NC=1C=C(C(C#N)=CC=1)C(F)(F)F)S(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-KRWDZBQOSA-N 0.000 description 1
- UZHVXJZEHGSWQV-UHFFFAOYSA-N 1,2,3,3a,4,5,6,6a-octahydrocyclopenta[c]pyrrole Chemical compound C1NCC2CCCC21 UZHVXJZEHGSWQV-UHFFFAOYSA-N 0.000 description 1
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
- FJQZXCPWAGYPSD-UHFFFAOYSA-N 1,3,4,6-tetrachloro-3a,6a-diphenylimidazo[4,5-d]imidazole-2,5-dione Chemical compound ClN1C(=O)N(Cl)C2(C=3C=CC=CC=3)N(Cl)C(=O)N(Cl)C12C1=CC=CC=C1 FJQZXCPWAGYPSD-UHFFFAOYSA-N 0.000 description 1
- VDFVNEFVBPFDSB-UHFFFAOYSA-N 1,3-dioxane Chemical compound C1COCOC1 VDFVNEFVBPFDSB-UHFFFAOYSA-N 0.000 description 1
- WNXJIVFYUVYPPR-UHFFFAOYSA-N 1,3-dioxolane Chemical compound C1COCO1 WNXJIVFYUVYPPR-UHFFFAOYSA-N 0.000 description 1
- IMLSAISZLJGWPP-UHFFFAOYSA-N 1,3-dithiolane Chemical compound C1CSCS1 IMLSAISZLJGWPP-UHFFFAOYSA-N 0.000 description 1
- HJTAZXHBEBIQQX-UHFFFAOYSA-N 1,5-bis(chloromethyl)naphthalene Chemical compound C1=CC=C2C(CCl)=CC=CC2=C1CCl HJTAZXHBEBIQQX-UHFFFAOYSA-N 0.000 description 1
- KQZLRWGGWXJPOS-NLFPWZOASA-N 1-[(1R)-1-(2,4-dichlorophenyl)ethyl]-6-[(4S,5R)-4-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]-5-methylcyclohexen-1-yl]pyrazolo[3,4-b]pyrazine-3-carbonitrile Chemical compound ClC1=C(C=CC(=C1)Cl)[C@@H](C)N1N=C(C=2C1=NC(=CN=2)C1=CC[C@@H]([C@@H](C1)C)N1[C@@H](CCC1)CO)C#N KQZLRWGGWXJPOS-NLFPWZOASA-N 0.000 description 1
- WZZBNLYBHUDSHF-DHLKQENFSA-N 1-[(3s,4s)-4-[8-(2-chloro-4-pyrimidin-2-yloxyphenyl)-7-fluoro-2-methylimidazo[4,5-c]quinolin-1-yl]-3-fluoropiperidin-1-yl]-2-hydroxyethanone Chemical compound CC1=NC2=CN=C3C=C(F)C(C=4C(=CC(OC=5N=CC=CN=5)=CC=4)Cl)=CC3=C2N1[C@H]1CCN(C(=O)CO)C[C@@H]1F WZZBNLYBHUDSHF-DHLKQENFSA-N 0.000 description 1
- XYKVTIPFANKIPK-UHFFFAOYSA-N 1-oxa-9-azaspiro[5.5]undecane Chemical compound O1CCCCC11CCNCC1 XYKVTIPFANKIPK-UHFFFAOYSA-N 0.000 description 1
- ABEXEQSGABRUHS-UHFFFAOYSA-N 16-methylheptadecyl 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCC(C)C ABEXEQSGABRUHS-UHFFFAOYSA-N 0.000 description 1
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 description 1
- KAESVJOAVNADME-UHFFFAOYSA-N 1H-pyrrole Natural products C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 1
- ODSNARDHJFFSRH-UHFFFAOYSA-N 2,3,3a,4,5,6,7,7a-octahydro-1h-isoindole Chemical compound C1CCCC2CNCC21 ODSNARDHJFFSRH-UHFFFAOYSA-N 0.000 description 1
- JKTCBAGSMQIFNL-UHFFFAOYSA-N 2,3-dihydrofuran Chemical compound C1CC=CO1 JKTCBAGSMQIFNL-UHFFFAOYSA-N 0.000 description 1
- 125000001917 2,4-dinitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C(=C1*)[N+]([O-])=O)[N+]([O-])=O 0.000 description 1
- WGFNXGPBPIJYLI-UHFFFAOYSA-N 2,6-difluoro-3-[(3-fluorophenyl)sulfonylamino]-n-(3-methoxy-1h-pyrazolo[3,4-b]pyridin-5-yl)benzamide Chemical compound C1=C2C(OC)=NNC2=NC=C1NC(=O)C(C=1F)=C(F)C=CC=1NS(=O)(=O)C1=CC=CC(F)=C1 WGFNXGPBPIJYLI-UHFFFAOYSA-N 0.000 description 1
- VPUPHJWCNCOITA-UHFFFAOYSA-N 2-(4-amino-4-methylpiperidin-1-yl)-5-(3-fluorophenyl)-6-oxo-1H-pyrimidine-4-carboxamide hydrochloride Chemical compound Cl.NC1(CCN(CC1)C1=NC(=C(C(=N1)C(=O)N)C1=CC(=CC=C1)F)O)C VPUPHJWCNCOITA-UHFFFAOYSA-N 0.000 description 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- DEJCFLFRHOUBJT-VWLOTQADSA-N 2-[(3S)-3-(tert-butylsulfanylamino)spiro[3H-1-benzofuran-2,4'-piperidine]-1'-yl]-5-(2,3-dichlorophenyl)-6-methylpyrimidine-4-carbonitrile Chemical compound C(C)(C)(C)SN[C@H]1C2=C(OC11CCN(CC1)C1=NC(=C(C(=N1)C#N)C1=C(C(=CC=C1)Cl)Cl)C)C=CC=C2 DEJCFLFRHOUBJT-VWLOTQADSA-N 0.000 description 1
- IKAYHVARHGIDOX-DEOSSOPVSA-N 2-[(3S)-3-(tert-butylsulfanylamino)spiro[3H-1-benzofuran-2,4'-piperidine]-1'-yl]-5-(2,3-dichlorophenyl)-6-methylpyrimidine-4-carboxamide Chemical compound C(C)(C)(C)SN[C@H]1C2=C(OC11CCN(CC1)C1=NC(=C(C(=N1)C(=O)N)C1=C(C(=CC=C1)Cl)Cl)C)C=CC=C2 IKAYHVARHGIDOX-DEOSSOPVSA-N 0.000 description 1
- AZDLVOLXVIREKE-UHFFFAOYSA-N 2-[(4-methylpiperazin-1-yl)methyl]bicyclo[2.2.1]heptan-3-one Chemical compound C1CN(C)CCN1CC1C(=O)C2CCC1C2 AZDLVOLXVIREKE-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- YSUIQYOGTINQIN-UZFYAQMZSA-N 2-amino-9-[(1S,6R,8R,9S,10R,15R,17R,18R)-8-(6-aminopurin-9-yl)-9,18-difluoro-3,12-dihydroxy-3,12-bis(sulfanylidene)-2,4,7,11,13,16-hexaoxa-3lambda5,12lambda5-diphosphatricyclo[13.2.1.06,10]octadecan-17-yl]-1H-purin-6-one Chemical compound NC1=NC2=C(N=CN2[C@@H]2O[C@@H]3COP(S)(=O)O[C@@H]4[C@@H](COP(S)(=O)O[C@@H]2[C@@H]3F)O[C@H]([C@H]4F)N2C=NC3=C2N=CN=C3N)C(=O)N1 YSUIQYOGTINQIN-UZFYAQMZSA-N 0.000 description 1
- TVTJUIAKQFIXCE-HUKYDQBMSA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynyl-1H-purine-6,8-dione Chemical compound NC=1NC(C=2N(C(N(C=2N=1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C)=O TVTJUIAKQFIXCE-HUKYDQBMSA-N 0.000 description 1
- PSNDWZOXFDKLLH-UHFFFAOYSA-N 2-azaspiro[3.4]octane Chemical compound C1NCC11CCCC1 PSNDWZOXFDKLLH-UHFFFAOYSA-N 0.000 description 1
- NINJAJLCZUYDGV-UHFFFAOYSA-N 2-azaspiro[4.4]nonane Chemical compound C1CCCC21CNCC2 NINJAJLCZUYDGV-UHFFFAOYSA-N 0.000 description 1
- ZHHBREJHLLBZIR-UHFFFAOYSA-N 2-chloro-5-(2,3-dichlorophenyl)-6-methylpyrimidine-4-carbonitrile Chemical compound ClC1=NC(=C(C(=N1)C#N)C1=C(C(=CC=C1)Cl)Cl)C ZHHBREJHLLBZIR-UHFFFAOYSA-N 0.000 description 1
- HXVQPZSXXYOZMP-UHFFFAOYSA-N 2-chloropyrimidine-4-carbonitrile Chemical compound ClC1=NC=CC(C#N)=N1 HXVQPZSXXYOZMP-UHFFFAOYSA-N 0.000 description 1
- ZWDVQMVZZYIAHO-UHFFFAOYSA-N 2-fluorobenzaldehyde Chemical compound FC1=CC=CC=C1C=O ZWDVQMVZZYIAHO-UHFFFAOYSA-N 0.000 description 1
- OFBVGDCXXGXDKU-UHFFFAOYSA-N 2-fluoropyridine-3-carbaldehyde Chemical compound FC1=NC=CC=C1C=O OFBVGDCXXGXDKU-UHFFFAOYSA-N 0.000 description 1
- CESUXLKAADQNTB-ZETCQYMHSA-N 2-methylpropane-2-sulfinamide Chemical compound CC(C)(C)[S@@](N)=O CESUXLKAADQNTB-ZETCQYMHSA-N 0.000 description 1
- ZHAIMJRKJKQNQI-UHFFFAOYSA-N 2-oxa-7-azaspiro[3.4]octane Chemical compound C1OCC11CNCC1 ZHAIMJRKJKQNQI-UHFFFAOYSA-N 0.000 description 1
- OXXXNXISRXFPBK-UHFFFAOYSA-N 2-oxa-8-azaspiro[4.5]decane Chemical compound C1OCCC21CCNCC2 OXXXNXISRXFPBK-UHFFFAOYSA-N 0.000 description 1
- QBWKPGNFQQJGFY-QLFBSQMISA-N 3-[(1r)-1-[(2r,6s)-2,6-dimethylmorpholin-4-yl]ethyl]-n-[6-methyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical compound N1([C@H](C)C2=NSC(NC=3C4=NC=C(N4C=C(C)N=3)C3=CNN=C3)=C2)C[C@H](C)O[C@H](C)C1 QBWKPGNFQQJGFY-QLFBSQMISA-N 0.000 description 1
- WFOVEDJTASPCIR-UHFFFAOYSA-N 3-[(4-methyl-5-pyridin-4-yl-1,2,4-triazol-3-yl)methylamino]-n-[[2-(trifluoromethyl)phenyl]methyl]benzamide Chemical compound N=1N=C(C=2C=CN=CC=2)N(C)C=1CNC(C=1)=CC=CC=1C(=O)NCC1=CC=CC=C1C(F)(F)F WFOVEDJTASPCIR-UHFFFAOYSA-N 0.000 description 1
- HGWUUOXXAIISDB-UHFFFAOYSA-N 3-azabicyclo[3.1.0]hexane Chemical compound C1NCC2CC21 HGWUUOXXAIISDB-UHFFFAOYSA-N 0.000 description 1
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 1
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 1
- AKJHMTWEGVYYSE-AIRMAKDCSA-N 4-HPR Chemical compound C=1C=C(O)C=CC=1NC(=O)/C=C(\C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C AKJHMTWEGVYYSE-AIRMAKDCSA-N 0.000 description 1
- MPMKMQHJHDHPBE-RUZDIDTESA-N 4-[[(2r)-1-(1-benzothiophene-3-carbonyl)-2-methylazetidine-2-carbonyl]-[(3-chlorophenyl)methyl]amino]butanoic acid Chemical compound O=C([C@@]1(N(CC1)C(=O)C=1C2=CC=CC=C2SC=1)C)N(CCCC(O)=O)CC1=CC=CC(Cl)=C1 MPMKMQHJHDHPBE-RUZDIDTESA-N 0.000 description 1
- 125000004606 5,6,7,8-tetrahydroisoquinolinyl group Chemical group C1(=NC=CC=2CCCCC12)* 0.000 description 1
- 125000004608 5,6,7,8-tetrahydroquinolinyl group Chemical group N1=C(C=CC=2CCCCC12)* 0.000 description 1
- UNFXIMAHZQAOEO-UHFFFAOYSA-N 5-(2,3-dichlorophenyl)-6-methyl-2-(3-oxospiro[1H-indene-2,4'-piperidine]-1'-yl)pyrimidine-4-carbonitrile Chemical compound ClC1=C(C=CC=C1Cl)C=1C(=NC(=NC=1C)N1CCC2(CC1)CC1=CC=CC=C1C2=O)C#N UNFXIMAHZQAOEO-UHFFFAOYSA-N 0.000 description 1
- 239000002677 5-alpha reductase inhibitor Substances 0.000 description 1
- SFZNEOXUOOCPME-UHFFFAOYSA-N 5-bromo-6-methyl-2-(3-oxospiro[1-benzofuran-2,4'-piperidine]-1'-yl)pyrimidine-4-carbonitrile Chemical compound BrC=1C(=NC(=NC=1C)N1CCC2(CC1)OC1=C(C2=O)C=CC=C1)C#N SFZNEOXUOOCPME-UHFFFAOYSA-N 0.000 description 1
- PSRRKEUWGUBUPD-UHFFFAOYSA-N 5-bromo-6-methyl-2-(3-oxospiro[1H-indene-2,4'-piperidine]-1'-yl)pyrimidine-4-carbonitrile Chemical compound BrC=1C(=NC(=NC=1C)N1CCC2(CC1)C(C1=CC=CC=C1C2)=O)C#N PSRRKEUWGUBUPD-UHFFFAOYSA-N 0.000 description 1
- LLENVBUPWUQAGL-UHFFFAOYSA-N 6,8-difluoro-7-hydroxy-4-methylcoumarin Chemical compound FC1=C(O)C(F)=CC2=C1OC(=O)C=C2C LLENVBUPWUQAGL-UHFFFAOYSA-N 0.000 description 1
- RSIWALKZYXPAGW-NSHDSACASA-N 6-(3-fluorophenyl)-3-methyl-7-[(1s)-1-(7h-purin-6-ylamino)ethyl]-[1,3]thiazolo[3,2-a]pyrimidin-5-one Chemical compound C=1([C@@H](NC=2C=3N=CNC=3N=CN=2)C)N=C2SC=C(C)N2C(=O)C=1C1=CC=CC(F)=C1 RSIWALKZYXPAGW-NSHDSACASA-N 0.000 description 1
- ONYACKMZXGHDJX-UHFFFAOYSA-N 6-amino-2-(4-amino-4-methylpiperidin-1-yl)-5-(2,3-dichlorophenyl)pyrimidine-4-carbonitrile Chemical compound CC1(N)CCN(CC1)C1=NC(N)=C(C(=N1)C#N)C1=CC=CC(Cl)=C1Cl ONYACKMZXGHDJX-UHFFFAOYSA-N 0.000 description 1
- PDRDRMDVWPOPFZ-UHFFFAOYSA-N 6-amino-2-chloropyrimidine-4-carboxamide Chemical compound NC(=O)C1=CC(N)=NC(Cl)=N1 PDRDRMDVWPOPFZ-UHFFFAOYSA-N 0.000 description 1
- ANQFJVOGDQEEIN-UHFFFAOYSA-N 6-amino-5-(2,3-dichlorophenyl)-2-[4-methyl-4-[(2-methylpropan-2-yl)oxycarbonylamino]piperidin-1-yl]pyrimidine-4-carboxylic acid Chemical compound NC1=C(C(=NC(=N1)N1CCC(CC1)(C)NC(=O)OC(C)(C)C)C(=O)O)C1=C(C(=CC=C1)Cl)Cl ANQFJVOGDQEEIN-UHFFFAOYSA-N 0.000 description 1
- JQDNSQCWDMONRP-UHFFFAOYSA-N 6-amino-5-(2,3-dichlorophenyl)-2-methylsulfanylpyrimidine-4-carbonitrile Chemical compound NC1=C(C(=NC(=N1)SC)C#N)C1=C(C(=CC=C1)Cl)Cl JQDNSQCWDMONRP-UHFFFAOYSA-N 0.000 description 1
- LENFJYUIAOAWPT-UHFFFAOYSA-N 6-amino-5-(7-chloro-1H-indazol-6-yl)-2-methylsulfonylpyrimidine-4-carbonitrile Chemical compound NC1=C(C(=NC(=N1)S(=O)(=O)C)C#N)C1=CC=C2C=NNC2=C1Cl LENFJYUIAOAWPT-UHFFFAOYSA-N 0.000 description 1
- NVZWMJWMTWOVNJ-UHFFFAOYSA-N 6-azaspiro[3.4]octane Chemical compound C1CCC21CNCC2 NVZWMJWMTWOVNJ-UHFFFAOYSA-N 0.000 description 1
- YZVKLYIQWYWMTA-UHFFFAOYSA-N 6-bromo-7-chloro-1H-indazole Chemical compound BrC1=CC=C2C=NNC2=C1Cl YZVKLYIQWYWMTA-UHFFFAOYSA-N 0.000 description 1
- ISUXMAHVLFRZQU-UHFFFAOYSA-N 6-chloro-2-methylsulfanylpyrimidin-4-amine Chemical compound CSC1=NC(N)=CC(Cl)=N1 ISUXMAHVLFRZQU-UHFFFAOYSA-N 0.000 description 1
- NUXAXXQWRZACAG-UHFFFAOYSA-N 6-methyl-2-(3-oxospiro[1H-indene-2,4'-piperidine]-1-yl)pyrimidine-4-carbonitrile Chemical compound CC1=CC(=NC(=N1)C1C2=CC=CC=C2C(C11CCNCC1)=O)C#N NUXAXXQWRZACAG-UHFFFAOYSA-N 0.000 description 1
- 125000003341 7 membered heterocyclic group Chemical group 0.000 description 1
- ANRMLYHEWFENLP-UHFFFAOYSA-N 7-chloro-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indazole Chemical compound CC1(C)OB(OC1(C)C)C1=C(Cl)C2=C(C=NN2)C=C1 ANRMLYHEWFENLP-UHFFFAOYSA-N 0.000 description 1
- UCDBLYHPJMMFMY-UHFFFAOYSA-N 8-bromoquinoline-4-carbonitrile Chemical compound C1=CN=C2C(Br)=CC=CC2=C1C#N UCDBLYHPJMMFMY-UHFFFAOYSA-N 0.000 description 1
- IRBAWVGZNJIROV-SFHVURJKSA-N 9-(2-cyclopropylethynyl)-2-[[(2s)-1,4-dioxan-2-yl]methoxy]-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one Chemical compound C1=C2C3=CC=C(C#CC4CC4)C=C3CCN2C(=O)N=C1OC[C@@H]1COCCO1 IRBAWVGZNJIROV-SFHVURJKSA-N 0.000 description 1
- SHGAZHPCJJPHSC-ZVCIMWCZSA-N 9-cis-retinoic acid Chemical compound OC(=O)/C=C(\C)/C=C/C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-ZVCIMWCZSA-N 0.000 description 1
- 206010000890 Acute myelomonocytic leukaemia Diseases 0.000 description 1
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 229920000856 Amylose Polymers 0.000 description 1
- 102000012936 Angiostatins Human genes 0.000 description 1
- 108010079709 Angiostatins Proteins 0.000 description 1
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
- 108091023037 Aptamer Proteins 0.000 description 1
- 101100248451 Arabidopsis thaliana RICE2 gene Proteins 0.000 description 1
- BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 description 1
- 102000015790 Asparaginase Human genes 0.000 description 1
- 108010024976 Asparaginase Proteins 0.000 description 1
- 102000036365 BRCA1 Human genes 0.000 description 1
- 108700020463 BRCA1 Proteins 0.000 description 1
- 101150072950 BRCA1 gene Proteins 0.000 description 1
- 102000052609 BRCA2 Human genes 0.000 description 1
- 108700020462 BRCA2 Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 101150008921 Brca2 gene Proteins 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 1
- 101710155857 C-C motif chemokine 2 Proteins 0.000 description 1
- KCBAMQOKOLXLOX-BSZYMOERSA-N CC1=C(SC=N1)C2=CC=C(C=C2)[C@H](C)NC(=O)[C@@H]3C[C@H](CN3C(=O)[C@H](C(C)(C)C)NC(=O)CCCCCCCCCCNCCCONC(=O)C4=C(C(=C(C=C4)F)F)NC5=C(C=C(C=C5)I)F)O Chemical compound CC1=C(SC=N1)C2=CC=C(C=C2)[C@H](C)NC(=O)[C@@H]3C[C@H](CN3C(=O)[C@H](C(C)(C)C)NC(=O)CCCCCCCCCCNCCCONC(=O)C4=C(C(=C(C=C4)F)F)NC5=C(C=C(C=C5)I)F)O KCBAMQOKOLXLOX-BSZYMOERSA-N 0.000 description 1
- LVRCEUVOXCJYSV-UHFFFAOYSA-N CN(C)S(=O)=O Chemical compound CN(C)S(=O)=O LVRCEUVOXCJYSV-UHFFFAOYSA-N 0.000 description 1
- DCERHCFNWRGHLK-UHFFFAOYSA-N C[Si](C)C Chemical compound C[Si](C)C DCERHCFNWRGHLK-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- OKTJSMMVPCPJKN-NJFSPNSNSA-N Carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 1
- 208000017897 Carcinoma of esophagus Diseases 0.000 description 1
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 108091006146 Channels Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 description 1
- HVXBOLULGPECHP-WAYWQWQTSA-N Combretastatin A4 Chemical compound C1=C(O)C(OC)=CC=C1\C=C/C1=CC(OC)=C(OC)C(OC)=C1 HVXBOLULGPECHP-WAYWQWQTSA-N 0.000 description 1
- 229940126657 Compound 17 Drugs 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 1
- 102000003849 Cytochrome P450 Human genes 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- WEAHRLBPCANXCN-UHFFFAOYSA-N Daunomycin Natural products CCC1(O)CC(OC2CC(N)C(O)C(C)O2)c3cc4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C1 WEAHRLBPCANXCN-UHFFFAOYSA-N 0.000 description 1
- 208000012239 Developmental disease Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- BUDQDWGNQVEFAC-UHFFFAOYSA-N Dihydropyran Chemical compound C1COC=CC1 BUDQDWGNQVEFAC-UHFFFAOYSA-N 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 208000006402 Ductal Carcinoma Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102400001047 Endostatin Human genes 0.000 description 1
- 108010079505 Endostatins Proteins 0.000 description 1
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 108010007508 Farnesyltranstransferase Proteins 0.000 description 1
- 108010029961 Filgrastim Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 102100039291 Geranylgeranyl pyrophosphate synthase Human genes 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004366 Glucose oxidase Substances 0.000 description 1
- 108010015776 Glucose oxidase Proteins 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 description 1
- 102000009465 Growth Factor Receptors Human genes 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 208000017891 HER2 positive breast carcinoma Diseases 0.000 description 1
- 101000656751 Haloarcula marismortui (strain ATCC 43049 / DSM 3752 / JCM 8966 / VKM B-1809) 30S ribosomal protein S24e Proteins 0.000 description 1
- 101000904173 Homo sapiens Progonadoliberin-1 Proteins 0.000 description 1
- 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 1
- 101001087394 Homo sapiens Tyrosine-protein phosphatase non-receptor type 1 Proteins 0.000 description 1
- 101001087416 Homo sapiens Tyrosine-protein phosphatase non-receptor type 11 Proteins 0.000 description 1
- LELOWRISYMNNSU-UHFFFAOYSA-N Hydrocyanic acid Natural products N#C LELOWRISYMNNSU-UHFFFAOYSA-N 0.000 description 1
- VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 1
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 1
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 description 1
- JJKOTMDDZAJTGQ-DQSJHHFOSA-N Idoxifene Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN2CCCC2)=CC=1)/C1=CC=C(I)C=C1 JJKOTMDDZAJTGQ-DQSJHHFOSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- WRYCSMQKUKOKBP-UHFFFAOYSA-N Imidazolidine Chemical compound C1CNCN1 WRYCSMQKUKOKBP-UHFFFAOYSA-N 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 102000013462 Interleukin-12 Human genes 0.000 description 1
- 108010065805 Interleukin-12 Proteins 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 102000004388 Interleukin-4 Human genes 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 241000764238 Isis Species 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- 230000004163 JAK-STAT signaling pathway Effects 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 1
- 208000005101 LEOPARD Syndrome Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 108010000817 Leuprolide Proteins 0.000 description 1
- 229940124041 Luteinizing hormone releasing hormone (LHRH) antagonist Drugs 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 238000003820 Medium-pressure liquid chromatography Methods 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 229920003094 Methocel™ K4M Polymers 0.000 description 1
- 206010062901 Multiple lentigines syndrome Diseases 0.000 description 1
- 101100288142 Mus musculus Klkb1 gene Proteins 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- 208000033835 Myelomonocytic Acute Leukemia Diseases 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- JRNVZBWKYDBUCA-UHFFFAOYSA-N N-Chlorosuccinimide Substances ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 description 1
- LQZMLBORDGWNPD-UHFFFAOYSA-N N-iodosuccinimide Substances IN1C(=O)CCC1=O LQZMLBORDGWNPD-UHFFFAOYSA-N 0.000 description 1
- OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 1
- 229910017917 NH4 Cl Inorganic materials 0.000 description 1
- 238000012565 NMR experiment Methods 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010029379 Neutrophilia Diseases 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 102000004459 Nitroreductase Human genes 0.000 description 1
- 206010029748 Noonan syndrome Diseases 0.000 description 1
- 208000010708 Noonan syndrome with multiple lentigines Diseases 0.000 description 1
- MSHZHSPISPJWHW-UHFFFAOYSA-N O-(chloroacetylcarbamoyl)fumagillol Chemical compound O1C(CC=C(C)C)C1(C)C1C(OC)C(OC(=O)NC(=O)CCl)CCC21CO2 MSHZHSPISPJWHW-UHFFFAOYSA-N 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 235000019502 Orange oil Nutrition 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 1
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 1
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 102100024028 Progonadoliberin-1 Human genes 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 102000014400 SH2 domains Human genes 0.000 description 1
- 108050003452 SH2 domains Proteins 0.000 description 1
- 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 1
- 241001522306 Serinus serinus Species 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- 101000996723 Sus scrofa Gonadotropin-releasing hormone receptor Proteins 0.000 description 1
- 238000006069 Suzuki reaction reaction Methods 0.000 description 1
- 230000017274 T cell anergy Effects 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 239000012317 TBTU Substances 0.000 description 1
- NAVMQTYZDKMPEU-UHFFFAOYSA-N Targretin Chemical compound CC1=CC(C(CCC2(C)C)(C)C)=C2C=C1C(=C)C1=CC=C(C(O)=O)C=C1 NAVMQTYZDKMPEU-UHFFFAOYSA-N 0.000 description 1
- 102000002938 Thrombospondin Human genes 0.000 description 1
- 108060008245 Thrombospondin Proteins 0.000 description 1
- 102000006601 Thymidine Kinase Human genes 0.000 description 1
- 108020004440 Thymidine kinase Proteins 0.000 description 1
- GCTFWCDSFPMHHS-UHFFFAOYSA-M Tributyltin chloride Chemical compound CCCC[Sn](Cl)(CCCC)CCCC GCTFWCDSFPMHHS-UHFFFAOYSA-M 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 101710204864 Tyrosine-protein phosphatase 2 Proteins 0.000 description 1
- 102100033001 Tyrosine-protein phosphatase non-receptor type 1 Human genes 0.000 description 1
- 108010042352 Urokinase Plasminogen Activator Receptors Proteins 0.000 description 1
- 102000004504 Urokinase Plasminogen Activator Receptors Human genes 0.000 description 1
- 206010047281 Ventricular arrhythmia Diseases 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 229940122803 Vinca alkaloid Drugs 0.000 description 1
- CLZISMQKJZCZDN-UHFFFAOYSA-N [benzotriazol-1-yloxy(dimethylamino)methylidene]-dimethylazanium Chemical compound C1=CC=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 CLZISMQKJZCZDN-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 208000011912 acute myelomonocytic leukemia M4 Diseases 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 229940009456 adriamycin Drugs 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- QBYJBZPUGVGKQQ-SJJAEHHWSA-N aldrin Chemical compound C1[C@H]2C=C[C@@H]1[C@H]1[C@@](C3(Cl)Cl)(Cl)C(Cl)=C(Cl)[C@@]3(Cl)[C@H]12 QBYJBZPUGVGKQQ-SJJAEHHWSA-N 0.000 description 1
- 229960000548 alemtuzumab Drugs 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 229960001445 alitretinoin Drugs 0.000 description 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 229960000473 altretamine Drugs 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 125000000747 amidyl group Chemical group [H][N-]* 0.000 description 1
- 125000004103 aminoalkyl group Chemical group 0.000 description 1
- 229960001220 amsacrine Drugs 0.000 description 1
- XCPGHVQEEXUHNC-UHFFFAOYSA-N amsacrine Chemical compound COC1=CC(NS(C)(=O)=O)=CC=C1NC1=C(C=CC=C2)C2=NC2=CC=CC=C12 XCPGHVQEEXUHNC-UHFFFAOYSA-N 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 229940045799 anthracyclines and related substance Drugs 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000002280 anti-androgenic effect Effects 0.000 description 1
- 229940046836 anti-estrogen Drugs 0.000 description 1
- 230000001833 anti-estrogenic effect Effects 0.000 description 1
- 230000003432 anti-folate effect Effects 0.000 description 1
- 230000003302 anti-idiotype Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000000051 antiandrogen Substances 0.000 description 1
- 229940030495 antiandrogen sex hormone and modulator of the genital system Drugs 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000002518 antifoaming agent Substances 0.000 description 1
- 229940127074 antifolate Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 238000012230 antisense oligonucleotides Methods 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 150000008209 arabinosides Chemical class 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 239000012300 argon atmosphere Substances 0.000 description 1
- 239000003886 aromatase inhibitor Substances 0.000 description 1
- 229940046844 aromatase inhibitors Drugs 0.000 description 1
- 125000003435 aroyl group Chemical group 0.000 description 1
- GOLCXWYRSKYTSP-UHFFFAOYSA-N arsenic trioxide Inorganic materials O1[As]2O[As]1O2 GOLCXWYRSKYTSP-UHFFFAOYSA-N 0.000 description 1
- 229960002594 arsenic trioxide Drugs 0.000 description 1
- 125000005098 aryl alkoxy carbonyl group Chemical group 0.000 description 1
- 125000005099 aryl alkyl carbonyl group Chemical group 0.000 description 1
- 125000005161 aryl oxy carbonyl group Chemical group 0.000 description 1
- 229960003272 asparaginase Drugs 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-M asparaginate Chemical compound [O-]C(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-M 0.000 description 1
- FZCSTZYAHCUGEM-UHFFFAOYSA-N aspergillomarasmine B Natural products OC(=O)CNC(C(O)=O)CNC(C(O)=O)CC(O)=O FZCSTZYAHCUGEM-UHFFFAOYSA-N 0.000 description 1
- XRWSZZJLZRKHHD-WVWIJVSJSA-N asunaprevir Chemical compound O=C([C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)OC1=NC=C(C2=CC=C(Cl)C=C21)OC)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C XRWSZZJLZRKHHD-WVWIJVSJSA-N 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- AXMNGEUJXLXFRY-UHFFFAOYSA-N azaspirodecane Chemical compound C1CCCC21CCNCC2 AXMNGEUJXLXFRY-UHFFFAOYSA-N 0.000 description 1
- ZSIQJIWKELUFRJ-UHFFFAOYSA-N azepane Chemical compound C1CCCNCC1 ZSIQJIWKELUFRJ-UHFFFAOYSA-N 0.000 description 1
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- XFILPEOLDIKJHX-QYZOEREBSA-N batimastat Chemical compound C([C@@H](C(=O)NC)NC(=O)[C@H](CC(C)C)[C@H](CSC=1SC=CC=1)C(=O)NO)C1=CC=CC=C1 XFILPEOLDIKJHX-QYZOEREBSA-N 0.000 description 1
- 229950001858 batimastat Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000005605 benzo group Chemical group 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 229950004221 besilate Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- 229960002938 bexarotene Drugs 0.000 description 1
- 229960000997 bicalutamide Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- LHHCSNFAOIFYRV-DOVBMPENSA-N boceprevir Chemical compound O=C([C@@H]1[C@@H]2[C@@H](C2(C)C)CN1C(=O)[C@@H](NC(=O)NC(C)(C)C)C(C)(C)C)NC(C(=O)C(N)=O)CC1CCC1 LHHCSNFAOIFYRV-DOVBMPENSA-N 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 238000010504 bond cleavage reaction Methods 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- BGECDVWSWDRFSP-UHFFFAOYSA-N borazine Chemical compound B1NBNBN1 BGECDVWSWDRFSP-UHFFFAOYSA-N 0.000 description 1
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- OVIZSQRQYWEGON-UHFFFAOYSA-N butane-1-sulfonamide Chemical compound CCCCS(N)(=O)=O OVIZSQRQYWEGON-UHFFFAOYSA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 230000009400 cancer invasion Effects 0.000 description 1
- 208000035269 cancer or benign tumor Diseases 0.000 description 1
- 229950002826 canertinib Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 1
- 229960000830 captopril Drugs 0.000 description 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
- 125000001589 carboacyl group Chemical group 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-N carbonic acid monoamide Natural products NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 229960005243 carmustine Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 238000004517 catalytic hydrocracking Methods 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- XGMFVZOKHBRUTL-UHFFFAOYSA-N chembl472004 Chemical compound C1=C(S(O)(=O)=O)C=CC2=CC(N=NC3=C(C4=NC=CC=C4C(=C3)S(O)(=O)=O)O)=CC=C21 XGMFVZOKHBRUTL-UHFFFAOYSA-N 0.000 description 1
- NMMPMZWIIQCZBA-UHFFFAOYSA-M chloropalladium(1+);dicyclohexyl-[2-[2,4,6-tri(propan-2-yl)phenyl]phenyl]phosphane;2-phenylethanamine Chemical compound [Pd+]Cl.NCCC1=CC=CC=[C-]1.CC(C)C1=CC(C(C)C)=CC(C(C)C)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 NMMPMZWIIQCZBA-UHFFFAOYSA-M 0.000 description 1
- 238000011097 chromatography purification Methods 0.000 description 1
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- 229960002436 cladribine Drugs 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 235000012716 cod liver oil Nutrition 0.000 description 1
- 239000003026 cod liver oil Substances 0.000 description 1
- 229960005537 combretastatin A-4 Drugs 0.000 description 1
- HVXBOLULGPECHP-UHFFFAOYSA-N combretastatin A4 Natural products C1=C(O)C(OC)=CC=C1C=CC1=CC(OC)=C(OC)C(OC)=C1 HVXBOLULGPECHP-UHFFFAOYSA-N 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 229940125773 compound 10 Drugs 0.000 description 1
- 229940125797 compound 12 Drugs 0.000 description 1
- 229940125758 compound 15 Drugs 0.000 description 1
- 229940125810 compound 20 Drugs 0.000 description 1
- 229940126086 compound 21 Drugs 0.000 description 1
- 229940126208 compound 22 Drugs 0.000 description 1
- 229940125833 compound 23 Drugs 0.000 description 1
- 229940125961 compound 24 Drugs 0.000 description 1
- 229940125846 compound 25 Drugs 0.000 description 1
- 229940125851 compound 27 Drugs 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 229940125877 compound 31 Drugs 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 239000007822 coupling agent Substances 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 229960000978 cyproterone acetate Drugs 0.000 description 1
- UWFYSQMTEOIJJG-FDTZYFLXSA-N cyproterone acetate Chemical compound C1=C(Cl)C2=CC(=O)[C@@H]3C[C@@H]3[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 UWFYSQMTEOIJJG-FDTZYFLXSA-N 0.000 description 1
- 229960000684 cytarabine Drugs 0.000 description 1
- 108010057085 cytokine receptors Proteins 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 229960003901 dacarbazine Drugs 0.000 description 1
- 229960000975 daunorubicin Drugs 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 230000030609 dephosphorylation Effects 0.000 description 1
- 238000006209 dephosphorylation reaction Methods 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 229960000605 dexrazoxane Drugs 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 150000004683 dihydrates Chemical class 0.000 description 1
- 125000000723 dihydrobenzofuranyl group Chemical group O1C(CC2=C1C=CC=C2)* 0.000 description 1
- 125000004582 dihydrobenzothienyl group Chemical group S1C(CC2=C1C=CC=C2)* 0.000 description 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- 239000001177 diphosphate Substances 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- WJJMNDUMQPNECX-UHFFFAOYSA-N dipicolinic acid Chemical compound OC(=O)C1=CC=CC(C(O)=O)=N1 WJJMNDUMQPNECX-UHFFFAOYSA-N 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- CETRZFQIITUQQL-UHFFFAOYSA-N dmso dimethylsulfoxide Chemical compound CS(C)=O.CS(C)=O CETRZFQIITUQQL-UHFFFAOYSA-N 0.000 description 1
- 239000003534 dna topoisomerase inhibitor Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 238000012912 drug discovery process Methods 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 230000008482 dysregulation Effects 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000001952 enzyme assay Methods 0.000 description 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 1
- 229960001904 epirubicin Drugs 0.000 description 1
- 208000037828 epithelial carcinoma Diseases 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 229960001433 erlotinib Drugs 0.000 description 1
- 201000005619 esophageal carcinoma Diseases 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000000328 estrogen antagonist Substances 0.000 description 1
- 102000015694 estrogen receptors Human genes 0.000 description 1
- 108010038795 estrogen receptors Proteins 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 229960000255 exemestane Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 108010036236 extracellular matrix receptor Proteins 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 229950003662 fenretinide Drugs 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 229960004177 filgrastim Drugs 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- DBEPLOCGEIEOCV-WSBQPABSSA-N finasteride Chemical compound N([C@@H]1CC2)C(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)NC(C)(C)C)[C@@]2(C)CC1 DBEPLOCGEIEOCV-WSBQPABSSA-N 0.000 description 1
- 229960004039 finasteride Drugs 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 description 1
- 229960000961 floxuridine Drugs 0.000 description 1
- 229960000390 fludarabine Drugs 0.000 description 1
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 150000005699 fluoropyrimidines Chemical class 0.000 description 1
- 239000004052 folic acid antagonist Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229960002584 gefitinib Drugs 0.000 description 1
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 230000008570 general process Effects 0.000 description 1
- 229940045109 genistein Drugs 0.000 description 1
- 235000006539 genistein Nutrition 0.000 description 1
- ZCOLJUOHXJRHDI-CMWLGVBASA-N genistein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 ZCOLJUOHXJRHDI-CMWLGVBASA-N 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940116332 glucose oxidase Drugs 0.000 description 1
- 235000019420 glucose oxidase Nutrition 0.000 description 1
- XLXSAKCOAKORKW-UHFFFAOYSA-N gonadorelin Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 XLXSAKCOAKORKW-UHFFFAOYSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- UUVWYPNAQBNQJQ-UHFFFAOYSA-N hexamethylmelamine Chemical compound CN(C)C1=NC(N(C)C)=NC(N(C)C)=N1 UUVWYPNAQBNQJQ-UHFFFAOYSA-N 0.000 description 1
- 102000044858 human PTPN11 Human genes 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 1
- 229960001330 hydroxycarbamide Drugs 0.000 description 1
- 229960000908 idarubicin Drugs 0.000 description 1
- 238000005417 image-selected in vivo spectroscopy Methods 0.000 description 1
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical compound C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 238000012739 integrated shape imaging system Methods 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 229940117681 interleukin-12 Drugs 0.000 description 1
- 229940028885 interleukin-4 Drugs 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 230000004068 intracellular signaling Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 206010073095 invasive ductal breast carcinoma Diseases 0.000 description 1
- 201000010985 invasive ductal carcinoma Diseases 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 229960004768 irinotecan Drugs 0.000 description 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- SHGAZHPCJJPHSC-XFYACQKRSA-N isotretinoin Chemical compound OC(=O)/C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-XFYACQKRSA-N 0.000 description 1
- 229960005280 isotretinoin Drugs 0.000 description 1
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
- 230000000366 juvenile effect Effects 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 1
- 229960004338 leuprorelin Drugs 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000005249 lung adenocarcinoma Diseases 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229940057948 magnesium stearate Drugs 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- OCSMOTCMPXTDND-OUAUKWLOSA-N marimastat Chemical compound CNC(=O)[C@H](C(C)(C)C)NC(=O)[C@H](CC(C)C)[C@H](O)C(=O)NO OCSMOTCMPXTDND-OUAUKWLOSA-N 0.000 description 1
- 229950008959 marimastat Drugs 0.000 description 1
- 229960004961 mechlorethamine Drugs 0.000 description 1
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 229960004296 megestrol acetate Drugs 0.000 description 1
- RQZAXGRLVPAYTJ-GQFGMJRRSA-N megestrol acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RQZAXGRLVPAYTJ-GQFGMJRRSA-N 0.000 description 1
- 229960001924 melphalan Drugs 0.000 description 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
- 210000003071 memory t lymphocyte Anatomy 0.000 description 1
- 239000003475 metalloproteinase inhibitor Substances 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- HNQIVZYLYMDVSB-UHFFFAOYSA-N methanesulfonimidic acid Chemical compound CS(N)(=O)=O HNQIVZYLYMDVSB-UHFFFAOYSA-N 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- NJJLYRIIIIXNPO-UHFFFAOYSA-N methyl 5-bromo-2-chloropyrimidine-4-carboxylate Chemical compound COC(=O)C1=NC(Cl)=NC=C1Br NJJLYRIIIIXNPO-UHFFFAOYSA-N 0.000 description 1
- BAKUCINLMVJHFO-UHFFFAOYSA-N methyl 6-amino-2-(4-amino-4-methylpiperidin-1-yl)-5-(2,3-dichlorophenyl)pyrimidine-4-carboxylate Chemical compound NC1=C(C(=NC(=N1)N1CCC(CC1)(C)N)C(=O)OC)C1=C(C(=CC=C1)Cl)Cl BAKUCINLMVJHFO-UHFFFAOYSA-N 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- DNIAPMSPPWPWGF-UHFFFAOYSA-N monopropylene glycol Natural products CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 230000036457 multidrug resistance Effects 0.000 description 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 1
- 210000002850 nasal mucosa Anatomy 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 210000003757 neuroblast Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 108020001162 nitroreductase Proteins 0.000 description 1
- OSTGTTZJOCZWJG-UHFFFAOYSA-N nitrosourea Chemical compound NC(=O)N=NO OSTGTTZJOCZWJG-UHFFFAOYSA-N 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 229940046166 oligodeoxynucleotide Drugs 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 239000010502 orange oil Substances 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 238000000643 oven drying Methods 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- OOFGXDQWDNJDIS-UHFFFAOYSA-N oxathiolane Chemical compound C1COSC1 OOFGXDQWDNJDIS-UHFFFAOYSA-N 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 230000004783 oxidative metabolism Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 125000003232 p-nitrobenzoyl group Chemical group [N+](=O)([O-])C1=CC=C(C(=O)*)C=C1 0.000 description 1
- 125000006503 p-nitrobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1[N+]([O-])=O)C([H])([H])* 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 238000012402 patch clamp technique Methods 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 238000001050 pharmacotherapy Methods 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- DCWXELXMIBXGTH-UHFFFAOYSA-N phosphotyrosine Chemical compound OC(=O)C(N)CC1=CC=C(OP(O)(O)=O)C=C1 DCWXELXMIBXGTH-UHFFFAOYSA-N 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229960003171 plicamycin Drugs 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 238000012746 preparative thin layer chromatography Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000009516 primary packaging Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- ZJLMKPKYJBQJNH-UHFFFAOYSA-N propane-1,3-dithiol Chemical compound SCCCS ZJLMKPKYJBQJNH-UHFFFAOYSA-N 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- BBFCIBZLAVOLCF-UHFFFAOYSA-N pyridin-1-ium;bromide Chemical compound Br.C1=CC=NC=C1 BBFCIBZLAVOLCF-UHFFFAOYSA-N 0.000 description 1
- YPOXGDJGKBXRFP-UHFFFAOYSA-N pyrimidine-4-carboxylic acid Chemical compound OC(=O)C1=CC=NC=N1 YPOXGDJGKBXRFP-UHFFFAOYSA-N 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 229960001404 quinidine Drugs 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000009790 rate-determining step (RDS) Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 239000012925 reference material Substances 0.000 description 1
- 230000025053 regulation of cell proliferation Effects 0.000 description 1
- 210000003289 regulatory T cell Anatomy 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 229960004641 rituximab Drugs 0.000 description 1
- 102200155478 rs121918459 Human genes 0.000 description 1
- 102200155720 rs121918465 Human genes 0.000 description 1
- 102200155722 rs121918465 Human genes 0.000 description 1
- 108091008601 sVEGFR Proteins 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000007974 sodium acetate buffer Substances 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- KSAVQLQVUXSOCR-UHFFFAOYSA-M sodium lauroyl sarcosinate Chemical compound [Na+].CCCCCCCCCCCC(=O)N(C)CC([O-])=O KSAVQLQVUXSOCR-UHFFFAOYSA-M 0.000 description 1
- 238000003797 solvolysis reaction Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 150000003413 spiro compounds Chemical class 0.000 description 1
- AJOICBZPOILCTP-UHFFFAOYSA-N spiro[1,3-dihydroindene-2,4'-piperidine] Chemical compound C1C2=CC=CC=C2CC11CCNCC1 AJOICBZPOILCTP-UHFFFAOYSA-N 0.000 description 1
- ZELCJNKQCKIECO-UHFFFAOYSA-N spiro[3h-1-benzofuran-2,4'-piperidine] Chemical compound C1C2=CC=CC=C2OC11CCNCC1 ZELCJNKQCKIECO-UHFFFAOYSA-N 0.000 description 1
- CGPCYJYORNBMRC-UHFFFAOYSA-N spiro[3h-indene-2,4'-piperidine]-1-one;hydrochloride Chemical compound Cl.O=C1C2=CC=CC=C2CC11CCNCC1 CGPCYJYORNBMRC-UHFFFAOYSA-N 0.000 description 1
- WTLOYBLDOJKPQS-UHFFFAOYSA-N spiro[4,6-dihydrocyclopenta[d][1,3]thiazole-5,4'-piperidine] Chemical compound N1CCC2(CC1)CC1=C(N=CS1)C2 WTLOYBLDOJKPQS-UHFFFAOYSA-N 0.000 description 1
- UOACDCSXSRJWCH-UHFFFAOYSA-N spiro[5,7-dihydrocyclopenta[b]pyridine-6,4'-piperidine] Chemical compound C1=CC=C2C(=N1)CC1(CCNCC1)C2 UOACDCSXSRJWCH-UHFFFAOYSA-N 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 230000004960 subcellular localization Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 150000003460 sulfonic acids Chemical class 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229940033134 talc Drugs 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 229940063683 taxotere Drugs 0.000 description 1
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 1
- 229960001278 teniposide Drugs 0.000 description 1
- UUYKESPPCQRBPT-UHFFFAOYSA-N tert-butyl 4-[2-(2-fluorophenyl)-1,3-dithian-2-yl]-4-hydroxypiperidine-1-carboxylate Chemical compound FC1=C(C=CC=C1)C1(SCCCS1)C1(CCN(CC1)C(=O)OC(C)(C)C)O UUYKESPPCQRBPT-UHFFFAOYSA-N 0.000 description 1
- SLIPOLMTJQEWOR-UHFFFAOYSA-N tert-butyl 4-[2-(2-fluoropyridin-3-yl)-1,3-dithian-2-yl]-4-hydroxypiperidine-1-carboxylate Chemical compound FC1=NC=CC=C1C1(SCCCS1)C1(CCN(CC1)C(=O)OC(C)(C)C)O SLIPOLMTJQEWOR-UHFFFAOYSA-N 0.000 description 1
- YDZQOKJHFNQCLR-UHFFFAOYSA-N tert-butyl N-[1-[4-amino-5-(2,3-dichlorophenyl)pyrimidin-2-yl]-4-methylpiperidin-4-yl]carbamate Chemical compound NC1=NC(=NC=C1C1=C(C(=CC=C1)Cl)Cl)N1CCC(CC1)(C)NC(OC(C)(C)C)=O YDZQOKJHFNQCLR-UHFFFAOYSA-N 0.000 description 1
- TVZWNCZYPUTITB-UHFFFAOYSA-N tert-butyl N-[1-[4-amino-6-carbamoyl-5-(3-fluorophenyl)pyrimidin-2-yl]-4-methylpiperidin-4-yl]carbamate Chemical compound NC1=NC(=NC(=C1C1=CC(=CC=C1)F)C(N)=O)N1CCC(CC1)(C)NC(OC(C)(C)C)=O TVZWNCZYPUTITB-UHFFFAOYSA-N 0.000 description 1
- XFQAVVLOKHZAAV-UHFFFAOYSA-N tert-butyl N-[1-[4-amino-6-cyano-5-(2,3-dichlorophenyl)pyrimidin-2-yl]-4-methylpiperidin-4-yl]carbamate Chemical compound C(C)(C)(C)OC(NC1(CCN(CC1)C1=NC(=C(C(=N1)N)C1=C(C(=CC=C1)Cl)Cl)C#N)C)=O XFQAVVLOKHZAAV-UHFFFAOYSA-N 0.000 description 1
- KFCURPZKQYZUKE-UHFFFAOYSA-N tert-butyl N-[1-[4-carbamoyl-5-(2,3-dichlorophenyl)pyrimidin-2-yl]-4-methylpiperidin-4-yl]carbamate Chemical compound C(N)(=O)C1=NC(=NC=C1C1=C(C(=CC=C1)Cl)Cl)N1CCC(CC1)(C)NC(OC(C)(C)C)=O KFCURPZKQYZUKE-UHFFFAOYSA-N 0.000 description 1
- LFKDJXLFVYVEFG-UHFFFAOYSA-N tert-butyl carbamate Chemical compound CC(C)(C)OC(N)=O LFKDJXLFVYVEFG-UHFFFAOYSA-N 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 description 1
- 238000003354 tissue distribution assay Methods 0.000 description 1
- 125000005425 toluyl group Chemical group 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 229940044693 topoisomerase inhibitor Drugs 0.000 description 1
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 1
- 229960000303 topotecan Drugs 0.000 description 1
- 229960005026 toremifene Drugs 0.000 description 1
- XFCLJVABOIYOMF-QPLCGJKRSA-N toremifene Chemical compound C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 XFCLJVABOIYOMF-QPLCGJKRSA-N 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 208000022679 triple-negative breast carcinoma Diseases 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 238000004724 ultra fast liquid chromatography Methods 0.000 description 1
- 238000001195 ultra high performance liquid chromatography Methods 0.000 description 1
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 1
- 238000001946 ultra-performance liquid chromatography-mass spectrometry Methods 0.000 description 1
- 239000004066 vascular targeting agent Substances 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 206010047302 ventricular tachycardia Diseases 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 description 1
- 229960002066 vinorelbine Drugs 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/14—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing 9-azabicyclo [3.3.1] nonane ring systems, e.g. granatane, 2-aza-adamantane; Cyclic acetals thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/10—Spiro-condensed systems
Abstract
Description
Srcホモロジー領域2(SH2)を含むタンパク質チロシンホスファターゼ2(SHP2)は、増殖、分化、細胞周期の維持及び遊走を含む複数の細胞機能に寄与するPTPN11遺伝子によりコードされた非受容体型タンパク質チロシンホスファターゼである。SHP2は、Ras-マイトジェン活性化プロテインキナーゼ経路、JAK-STAT経路又はホスホイノシトール3-キナーゼ-AKT経路を介したシグナリングに関与している。SHP2は、2つのN-末端Srcホモロジー2ドメイン(N-SH2及びC-SH2)、触媒ドメイン(PTP)、及びC-末端尾部を有する。この2つのSH2ドメインは、SHP2の細胞下局在化及び機能調節を制御する。この分子は、N-SH2ドメイン及びPTPドメインの両方に由来する残基が関与する結合ネットワークにより安定化された、不活性の自己阻害立体配座で存在する。例えばサイトカイン又は成長因子による刺激は、触媒部位の露出に繋がり、SHP2の酵素的活性化を生じる。
驚くべきことに、本発明のカルボキサミド-ピリミジン誘導体は、SHP2の高度に効果的な阻害薬であること、従ってこれらは、癌などの高増殖性疾患及び障害の治療のために使用することができることがわかった。
R1は、3~14個の炭素原子並びにN、O及びSから独立して選択された0~4個のヘテロ原子を含む、単環式-又は二環式のアルキル、ヘテロシクリル、ヘテロアリール又は二環式アルキルアリールであり、これは非置換であるか、又は(CH2)nNH2、(CH2)nOH、(CH2)nCH3もしくはHalにより一-、二-又は三-置換されており、
Xは、単結合、-NH又は-N(CH3)-、(CH2)n又はOであり、
R2は、非置換であるか、又は(CH2)nNH2、(CH2)nOH、COOH、CONH2、アルキル、=S、=O、=NH、CNもしくはHalにより一-、二-又は三置換されている、アリール又はヘテロアリール、S-アリール又はS-ヘテロアリールであり、
R3は、H、NH2、OH、Hal又はアルキルであり、
Yは、N又はOであり、
R4、R5は、両方共Hであるか、又はR4及びR5の一方は、OH、COOH、NH2、CONH2、又は非置換であるか、もしくは=S、=O、OH、COOH、=NH、NH2、CONH2により置換されたメチルもしくはエチルであり、
Halは、F、Cl、Br、又はIであり、
nは、0、1、2又は3である)
のカルボキサミド-ピリミジン誘導体、並びに、それらの生理的に許容し得る塩、誘導体、溶媒和物、プロドラッグ、立体異性体及びアトロプ異性体であって、あらゆる比のそれらの混合物を含むものに関する。
R1は、モノシクロアルキル、ビシクロアルキル、モノヘテロシクリル又はビヘテロシクリルであり、そのいずれかは、任意にモノシクロアルキル、ビシクロアルキル、モノヘテロシクリル、又はビヘテロシクリルに結合されたスピロであり、そのモノ-もしくはビ-シクロアルキル及びヘテロシクリルの各々は、C1-C6アルキル、-F、-Cl、-CF3、-NH2、C1-C3アミノアルキル、-OH、C1-C3アルコキシ、C1-C3ヒドロキシアルキル及びフェニルから選択された1~3個の基により、各々任意に及び独立して置換されてよく;
Xは、結合、-NH-又は-N(Me)-であり;
R2は、-F、-Cl、-CF3、C1-C3アルコキシ及びC1-C3アルキルから選択された1~3個の基により置換されている、アリール又はヘテロアリールであり;
R3は、-H、-NH2、-OH、-Cl、-F、-Br、又は-CH3であり;
Yは、-Nであり;並びに
R4及びR5は、独立して-H、-NH2、-OH、C1-C3アルキル、又はC1-C3ヒドロキシアルキルである)。
R1は:
R6、R7及びR8の各々は、-H、-F、-Cl、-CF3、C1-C3アルコキシ及びC1-C3アルキルから独立して選択され;
nは、0、1、2、又は3であり;並びに
R9、R10、R11、R12、R13、R14、R15及びR16の各々は、存在する場合、-H、C1-C3アルキル、-NH2、-OH、-Cl、-F、-Br、C1-C3アミノアルキル、C1-C3ヒドロキシアルキル、C1-C3アルコキシ、及びフェニルから独立して選択されるか;或いは
R9、R11、R13及びR16の2つは、一緒に、任意にC1-C3アルキル、-NH2、-OH、-Cl、-F、-Br、C1-C3アミノアルキル、C1-C3ヒドロキシアルキル、C1-C3アルコキシ、及びフェニルから選択される1~3個の置換基により任意に置換された、架橋した二環式複素環系を形成するか;或いは
同じ炭素原子に結合されている、R9、R10、R11、R12、R13、R14、R15、及びR16の2つは、一緒に、C1-C3アルキル、-NH2、-OH、-Cl、-F、-Br、C1-C3アミノアルキル、C1-C3ヒドロキシアルキル、C1-C3アルコキシ、及びフェニルから選択される1~3個の置換基により任意に置換された、単環式又は二環式のスピロシクリルを形成するか;或いは
隣接炭疽原子に結合されている、R9、R10、R11、R12、R13、R14、R15、及びR16の2つは、一緒に、C1-C3アルキル、-NH2、-OH、-Cl、-F、-Br、C1-C3アミノアルキル、C1-C3ヒドロキシアルキル、C1-C3アルコキシ、及びフェニルから選択される1~3個の置換基により任意に置換された、縮合されたカルボシクリル又はヘテロシクリルを形成し;
並びに、残りの変動は、上記式Iについて説明された意味を有する。
R6、R7及びR8の各々は、-H、-F、-Cl、-CF3、C1-C3アルコキシ及びC1-C3アルキルから独立して選択され;
nは、0、1、2、又は3であり;並びに
R9、R10、R11、R12、R13、R14、R15及びR16の各々は、存在する場合、-H、C1-C3アルキル、-NH2、-OH、-Cl、-F、-Br、C1-C3アミノアルキル、C1-C3ヒドロキシアルキル、C1-C3アルコキシ、及びフェニルから独立して選択されるか;或いは
R9、R11、R13及びR16の2つは、一緒に、任意にC1-C3アルキル、-NH2、-OH、-Cl、-F、-Br、C1-C3アミノアルキル、C1-C3ヒドロキシアルキル、C1-C3アルコキシ、及びフェニルから選択される1~3個の置換基により任意に置換された、架橋した二環式複素環系を形成するか;或いは
同じ炭素原子に結合されている、R9、R10、R11、R12、R13、R14、R15、及びR16の2つは、一緒に、C1-C3アルキル、-NH2、-OH、-Cl、-F、-Br、C1-C3アミノアルキル、C1-C3ヒドロキシアルキル、C1-C3アルコキシ、及びフェニルから選択される1~3個の置換基により任意に置換された、単環式又は二環式のスピロシクリルを形成するか;或いは
隣接炭疽原子に結合されている、R9、R10、R11、R12、R13、R14、R15、及びR16の2つは、一緒に、C1-C3アルキル、-NH2、-OH、-Cl、-F、-Br、C1-C3アミノアルキル、C1-C3ヒドロキシアルキル、C1-C3アルコキシ、及びフェニルから選択される1~3個の置換基により任意に置換された、縮合されたカルボシクリル又はヘテロシクリルを形成する。
a)有効量の式Iの化合物、並びに/又は全ての比のそれらの混合物を含む、それらの生理的に許容し得る塩、誘導体、溶媒和物、プロドラッグ、立体異性体及びアトロプ異性体、並びに
b)有効量の更なる医薬活性化合物:の個別のパックからなる、セット(キット)にも関する。
(i)内科的腫瘍学において使用されるような、抗増殖性/抗新生物形成性/DNA-損傷性の活性化合物及びその組合せ、例としてアルキル化剤(例えば、シスプラチン、パルボプラチン、シクロホスファミド、ナイトロジェンマスタード、メルファラン、クロラムブシル、ブスルファン及びニトロソ尿素);代謝拮抗薬(例えば、抗葉酸エステル、例として、5-フルオロウラシル及びテガファーなどのフルオロピリミジン、ラルチトレキセド、メトトレキセート、シトシンアラビノシド、ヒドロキシ尿素及びゲムシタビン);抗腫瘍抗生物質(例えば、アントラサイクリン、例としてアドリアマイシン、ブレオマイシン、ドキソルビシン、ダウノマイシン、エピルビシン、イダルビシン、マイトマイシン-C、ダクチノマイシン及びミトラマイシン);抗有糸分裂剤(例えば、ビンカ・アルカロイド、例として、ビンクリスチン、ビンブラスチン、ビンデシン及びビノレルビン、並びにタキソイド、例としてタキソール及びタキソテレ);トポイソメラーゼ阻害剤(例えば、エピポドフィロトキシン、例としてエトポシド及びテニポシド、アムサクリン、トポテカン、イリノテカン及びカンプトテシン)、並びに細胞分化誘導剤(例えば、全-trans-レチノイン酸、13-cis-レチノイン酸及びフェンレチニド)など;
(ii)細胞分裂阻害性剤、例えば抗-オエストロゲン(例えば、タモキシフェン、トレミフェン、ラロキシフェン、ドロロキシフェン及びヨードキシフェン)、オエストロゲン受容体調節因子(例えば、フルベストラント)、抗-アンドロゲン薬(例えば、ビカルタミド、フルタミド、ニルタミド及び酢酸シプロテロン)、LHRHアンタゴニスト又はLHRHアゴニスト(例えば、ゴセレリン、ロイプロレリン及びブセレリン)、プロゲステロン(例えば、酢酸メゲストロール)、アロマターゼ阻害剤(例えば、アナストラゾール、レトロゾール、ボラゾール及びエクセメスタン)並びに5α-レダクターゼ阻害剤、例えばフィナステリドなど;
(iii)癌侵襲を阻害する活性化合物、例えば、マリマスタットのような、メタロプロテイナーゼ阻害剤、並びにウロキナーゼプラスミノーゲン活性化因子受容体機能の阻害剤;
(iv)例えば、成長因子抗体、成長因子受容体抗体などの、成長因子機能の阻害剤、例えば抗-erbb2抗体トラスツズマブ[ハーセプチン(商標)]及び抗-erbbl抗体セツキシマブ[C225])、ファルネシル転移酵素阻害剤、チロシンキナーゼ阻害剤及びセリン/トレオニンキナーゼ阻害剤、例として、上皮細胞成長因子ファミリーの阻害剤(例えば、EGFRファミリーチロシンキナーゼ阻害剤、例として、N(3-クロロ-4-フルオロフェニル)-7-メトキシ-6-(3-モルホリノプロポキシ)キナゾリン-4-アミン(ゲフィチニブ、AZD1839)、N-(3-エチニルフェニル)-6,7ビス(2-メトキシエトキシ)-キナゾリン-4-アミン(エルロチニブ、OSI-774)及び6アクリルアミド-N-(3-クロロ-4-フルオロフェニル)-7-(3-モルホリノプロポキシ)キナゾリン-4-アミン(CI 1033)、例えば、血小板-由来成長因子ファミリーの阻害薬、例えば、肝細胞成長因子ファミリーの阻害薬;
(v)抗血管新生薬、例えばベバシズマブ、アンギオスタチン、エンドスタチン、リノミド、バチマスタット、カプトプリル、軟骨由来の阻害薬、ゲニステイン、インターロイキン12、ラベンダスチン、メロドキシプロゲステロン酢酸エステル、組換えヒト血小板第4因子、テコガラン、トロンボスポンジン、TNP-470、抗-VEGFモノクローナル抗体、可溶性VEGF-受容体キメラタンパク質、抗-VEGF受容体抗体、抗-PDGF受容体、インテグリンの阻害剤、チロシンキナーゼ阻害剤、セリン/トレオニンキナーゼ阻害剤、アンチセンスオリゴヌクレオチド、アンチセンスオリゴデオキシヌクレオチド、siRNA、抗-VEGFアプタマー、色素上皮由来因子、並びに国際特許出願WO97/22596、WO97/30035、WO97/32856及びWO98/13354に公開された化合物);
(vi)血管破壊薬、例としてコンブレタスタチンA4、並びに国際特許出願WO99/02166、WO00/40529、WO00/41669、WO01/92224、WO02/04434及びWO02/08213に公開された化合物;
(vii)アンチセンス療法、例えば、前述の標的に指向性のあるもの、例としてISIS 2503、抗-Rasアンチセンス;
(viii)例えば、異常なp53又は異常なBRCA1もしくはBRCA2などの、異常な修飾された遺伝子の置き換えのためのアプローチを含む、遺伝子治療アプローチ、GDEPTアプローチ(遺伝子-指向性酵素プロドラッグ療法)、例として、シトシンデアミナーゼ、チミジンキナーゼ又は細菌性ニトロレダクターゼ酵素を使用するもの、並びに化学療法又は放射線治療に対する、患者の忍容性を増大するアプローチ、例えば多剤抵抗性療法;並びに
(ix)例えば、患者の腫瘍細胞の免疫原性を増大するためのエクスビボ及びインビボのアプローチ、例としてインターロイキン2、インターロイキン4又は顆粒球マクロファージコロニー刺激因子などのサイトカインによるトランスフェクション、T細胞アネルギーを減少するアプローチ、サイトカイン-トランスフェクションされた樹状細胞などの、トランスフェクションされた免疫細胞を使用するアプローチ、サイトカイン-トランスフェクションされた腫瘍細胞を使用するアプローチ、並びに抗-イディオタイプ抗体を使用するアプローチを含む、免疫療法的アプローチ;
(x)例えばアバレリクス、アルデスロイキン、アレムツズマブ、アリトレチノイン、アロプリノール、アルトレタミン、アミホスチン、アナストラゾール、三酸化ヒ素、アスパラギナーゼ、生BCG、ベバシズマブ、ベキサロテン、ブレオマイシン、ボルテゾミブ、ブスルファン、カルステロン、カンプトテシン、カペシタビン、カルボプラチン、カルムスチン、セレコキシブ、セツキシマブ、クロラムブシル、シナカルセト、シスプラチン、クラドリビン、シクロホスファミド、シタラビン、ダカルバジン、ダクチノマイシン、ダルベポエチンα、ダウノルビシン、デニロイキンディフチトクス、デキスラゾキサン、ドセタキセル、ドキソルビシン、ドロモスタノロン、エピルビシン、エポエチンα、エストラムスチン、エトポシド、エクセメスタン、フィルグラスチム、フロクスウリジン、フルダラビン、フルオロウラシル、フルベストラント及びゲムシタビン含む、化学療法薬。
AUC 血漿中薬物濃度-時間曲線下面積
Cmax 最大血漿中濃度
CL クリアランス
CV 変動係数
CYP シトクロムP450
DMSO ジメチルスルホキシド
%F 生物学的利用能
fa 吸収率
iv 静脈内
LC-MS/MS 液体クロマトグラフィータンデム質量分析
LLOQ 定量下限
NC 計算せず
NT 試験せず
PEG ポリエチレングリコール
Pgp 透過性糖タンパク質
PK 薬物動態(複数可)
po 口から(経口)
t1/2 半減期
tmax 薬物の最大血漿濃度に到達する時間
UPLC 超高速液体クロマトグラフィー
Vss 分布容積(定常状態で)
v/v 容積対容積
本発明は、表2の化合物及びそれらの生理的に許容し得る塩、誘導体、溶媒和物、プロドラッグ、立体異性体及びアトロプ異性体であって、全ての比率のこれらの混合物を含むものに関する。
下記の略語は、以下の意味を有する:
Boc ter-ブトキシカルボニル
CBZ ベンジルオキシカルボニル
DNP 2,4-ジニトロフェニル
FMOC 9-フルオレニルメトキシカルボニル
imi-DNP イミダゾール環の1位の2,4-ジニトロフェニル
OMe メチルエステル
POA フェノキシアセチル
DCCI ジシクロヘキシルカルボジイミド
HOBt 1-ヒドロキシベンゾトリアゾール
ピリミジン1(式中、R3及びR8は、先に記載されており、並びにLG1は、ハロゲン又はOMs、OTs、OTfなどの脱離基である)は、アミンNHR20R21(式中、R20及びR21は、先に記載されている)により、TEA、DIEA、Cs2CO3又はK2CO3などの塩基の存在又は非存在下で、非限定的にMeOH、EtOH、DMF、DMSOなどの溶媒中で加熱することにより、置換反応を受け、一般式2のピリミジン(式中、R3、R20、R21及びR8は、先に規定されている)を生じる。次にピリジン2は、例えば、NBS、NCS又はNISを使用するハロゲン化条件に供され、一般式3の中間体(式中、R3、R20、R21及びR8は、先に説明されており、並びにHalは、Cl、Br又はIなどのハロゲン原子である)を生じる。最後に、ピリミジン3は、当業者に周知の標準条件を使用し、クロスカップリング反応を受け、ピリミジン4を生じる。一部の実施態様において、クロスカップリング反応は、鈴木反応であるが、他のクロスカップリング反応を利用してもよい。
この反応の配列において、チオメチル化合物5(式中、R3及びR8は、先に規定されている)は、最初にハロゲン化条件に、次にクロスカップリング条件に供され、中間体化合物7(式中、R2、R3、R8は、先に規定されている)を生じる。その後チオメチル基は、例えばmCPBA又はH2O2のような、当業者に周知の標準条件を使用し、SO2Meへ酸化され、中間体8(式中、R2、R3及びR8は、先に規定されている)を生じる。最後に、中間体8は、NHR20R21(式中、R20及びR21は、先に規定されている)による置換反応を受ける。
R8がCNである場合、一般式Iの最終化合物(式中、R2、R3、R4、R20及びR21は、先に規定されている)は、一般式4bの化合物(式中、R2、R3、R5及びR7は、先に規定されている)の加水分解により、一般式9の酸(式中、R2、R3、R5及びR7は、次にスキーム4に描かれたような.アミドカップリング反応を受ける)を得ることができる。或いは、一般式Ibの化合物は、一般式4bの化合物(式中、R2、R3、R5及びR7)の、DMF又はDMSO中のNaOH及びH2O2の存在下での加熱など、当業者に周知の条件を使用する、直接加水分解により得ることができる。
他の一般式Iの化合物の合成のために、類似の合成スキームには、各分子の具体的置換基に適合された適切な修飾を適用されるべきであり、そのような要因は、当業者に理解される。
Ac(アセチル);ACN(アセトニトリル);atm(大気圧);DIEA(ジイソプロピルエチルアミン);℃(摂氏度);DMF(ジメチルホルムアミド);DMSO(ジメチルスルホキシド);dppf(1,1’-ビス-ジフェニルホスフィンフェロセン);EtOAc(酢酸エチル);g(グラム);h(時);HATU(N-[(ジメチルアミノ)(3H-[1,2,3]トリアゾロ[4,5-b]ピリジン-3-イルオキシ)メチレン]-N-メチルメタナミニウムヘキサフルオロリン酸);HOBt(ヒドロキシベンゾトリアゾール);HPLC(高速液体クロマトグラフィー);h(時間);LC(液体クロマトグラフィー);LDA(リチウムジイソプロピルアミド);MeOH(メタノール);min(分);mL(ミリリットル);mmol(ミリモル);MS(質量分析);NBS(N-ブロモスクシンイミド);NMR(核磁気共鳴);O/N(一晩);PE(石油エーテル);RT(室温);TBDMS(tert-ブチルジメチルシリル);TEA(トリエチルアミン);TFA(トリフルオロ酢酸);THF(テトラヒドロフラン);TMS(トリメチルシリル)。
工程1:tert-ブチル(1-(4-シアノピリミジン-2-イル)-4-メチルピペリジン-4-イル)カルバメート
工程1:tert-ブチル N-[1-(4-アミノ-6-カルバモイルピリミジン-2-イル)-4-メチルピペリジン-4-イル]カルバメート
工程1:6-アミノ-2-(メチルスルファニル)ピリミジン-4-カルボニトリル
工程1:tert-ブチル N-[1-(4-シアノ-6-メチルピリミジン-2-イル)-4-メチルピペリジン-4-イル]カルバメート
工程1:tert-ブチル N-[(3S,4S)-8-(4-シアノ-6-メチルピリミジン-2-イル)-3-メチル-2-オキサ-8-アザスピロ[4.5]デカン-4-イル]カルバメート
工程1:tert-ブチル N-[(1R)-8-(4-シアノ-6-メチルピリミジン-2-イル)-3,3-ジフルオロ-8-アザスピロ[4.5]デカン-1-イル]カルバメート
工程1:tert-ブチル N-[(1R)-8-(4-シアノ-6-メチルピリミジン-2-イル)-8-アザスピロ[4.5]デカン-1-イル]カルバメート
工程1:2-(2-フルオロフェニル)-1,3-ジチアン
工程1:3-(1,3-ジチアン-2-イル)-2-フルオロピリジン
工程1:tert-ブチル (4Z)-2-クロロ-4-{[(R)-2-メチルプロパン-2-スルフィニル]イミノ}-4,6-ジヒドロスピロ[シクロペンタ[d][1,3]チアゾール-5,4’-ピペリジン]-1’-カルボキシラート
工程1:tert-ブチル (1-(4-シアノ-5-(2,3-ジクロロフェニル)ピリミジン-2-イル)-4-メチルピペリジン-4-イル)カルバメートの合成
工程1:tert-ブチル N-{1-[4-アミノ-6-カルバモイル-5-(3-クロロフェニル)ピリミジン-2-イル]-4-メチルピペリジン-4-イル}カルバメート
工程1:6-アミノ-2-(4-アミノ-4-メチル-ピペリジン-1-イル)-5-(2,3-ジクロロ-フェニル)-ピリミジン-4-カルボニトリルビス-トリフルオロ酢酸エステル
アトロプ異性体3(200mg)の混合物は、SFC((R,R)WHELK-01、4.6×150mm、5um、EtOH+0.1% DEA:CO2、0-50%)により分離した。
工程1:tert-ブチル N-{1-[4-アミノ-6-カルバモイル-5-(2,3-ジクロロフェニル)ピリミジン-2-イル]-4-メチルピペリジン-4-イル}カルバメート
工程1:tert-ブチル N-{1-[4-シアノ-5-(2,3-ジクロロフェニル)-6-メチルピリミジン-2-イル]-4-メチルピペリジン-4-イル}カルバメート
工程1:tert-ブチル N-{1-[4-アミノ-6-カルバモイル-5-(3-フルオロフェニル)ピリミジン-2-イル]-4-メチルピペリジン-4-イル}カルバメート
工程1:メチル 6-アミノ-2-(4-アミノ-4-メチルピペリジン-1-イル)-5-(2,3-ジクロロフェニル)ピリミジン-4-カルボキシラート
工程1:tert-ブチル N-{1-[4-アミノ-5-(2,3-ジクロロフェニル)-6-(ヒドラジンカルボニル)-ピリミジン-2-イル]-4-メチルピペリジン-4-イル}カルバメート
工程1:tert-ブチル N-[(3S,4S)-8-[4-アミノ-6-シアノ-5-(2,3-ジクロロフェニル)ピリミジン-2-イル]-3-メチル-2-オキサ-8-アザスピロ[4.5]デカン-4-イル]カルバメート
工程1:tert-ブチル N-[(3S,4S)-8-[4-シアノ-5-(2,3-ジクロロフェニル)-6-メチルピリミジン-2-イル]-3-メチル-2-オキサ-8-アザスピロ[4.5]デカン-4-イル]カルバメート
工程1:rac-2-[(3aS,6aR)-3a-(アミノメチル)-オクタヒドロシクロペンタ[c]ピロール-2-イル]-6-アミノ-5-(2,3-ジクロロフェニル)ピリミジン-4-カルボキサミド
工程1:2-[3a-(アミノメチル)-オクタヒドロ-1H-イソインドール-2-イル]-6-アミノ-5-(2,3-ジクロロフェニル)ピリミジン-4-カルボキサミド
工程1:6-アミノ-2-[(1S)-1-アミノ-1,3-ジヒドロスピロ[インデン-2,4’-ピペリジン]-1’-イル]-5-(2,3-ジクロロフェニル)ピリミジン-4-カルボニトリル
工程1:6-メチル-2-{1-オキソ-1,3-ジヒドロスピロ[インデン-2,4’-ピペリジン]-1’-イル}ピリミジン-4-カルボニトリル
工程1:6-アミノ-2-[(4S)-4-アミノ-4,6-ジヒドロスピロ[シクロペンタ[d][1,3]チアゾール-5,4’-ピペリジン]-1’-イル]-5-(2,3-ジクロロフェニル)ピリミジン-4-カルボニトリル
工程1:6-メチル-2-[3-オキソスピロ[1-ベンゾフラン-2,4-ピペリジン]-1-イル]ピリミジン-4-カルボニトリル
工程1:6-アミノ-2-[(3S)-3-アミノ-3H-スピロ[1-ベンゾフラン-2,4’-ピペリジン]-1’-イル]-5-(2,3-ジクロロフェニル)ピリミジン-4-カルボニトリル
工程1:2-[3-アミノ-3H-スピロ[フロ[2,3-b]ピリジン-2,4’-ピペリジン]-1’-イル]-5-(2,3-ジクロロフェニル)-6-メチルピリミジン-4-カルボニトリル
工程1:6-アミノ-2-[3-アミノ-3H-スピロ[フロ[2,3-b]ピリジン-2,4-ピペリジン]-1-イル]-5-(2,3-ジクロロフェニル)ピリミジン-4-カルボニトリル
SHP2生化学アッセイ:
本発明の化合物によるSHP2の阻害を、2個の適切に間隔があいたホスホチロシンを有するペプチドによるタンパク質活性化後に、代理基質DiFMUPを用いてモニタリングした。完全長SHP2タンパク質(組換えヒトSHP-2、大腸菌由来のSer2Arg593、R&D systemsのN-末端6Hisタグ;0.0.24nM)を、活性化ペプチド、IRSI_2pY(New England Peptide、140nM)及びDiFMUP(Molecular Probes、80uM)と共に、緩衝液(HEPES、pH7.2、60mM、DDT 5mM、KCl 75mM、NaCl 75mM、EDTA 1mM、Tween20 0.05%)中で、化合物の存在下(10濃度範囲、最高濃度50μM)、RTで60分間インキュベーションした。活性化されたSHP2によるDiFMU生成物の生成は、PerkinElmer Envisionリーダーによる蛍光測定によりモニタリングした。阻害-用量反応曲線は、Genedata Screenerにより分析した。本発明の化合物に関するIC50範囲は、下記表4に示している。
SHP2阻害剤のpERKレベルに対する効果を、メソ解析定量プラットフォームを使用し、ホスホ-特異的抗体を用いて評価した。メソ解析を使用するpERKレベルの変化の測定に関して、MDA MB468細胞及びKYSE520細胞の30,000個細胞を、培地容積175ulで、96-ウェル組織培養用の処理したプレートに播種した。37℃で一晩インキュベーションした後、様々なSHP2阻害剤を、プレートにわたり2つ組のウェルを維持している各ウェルに、異なる濃度で添加し、化合物と共に、37℃で2hインキュベーションし、その後氷冷したPBS緩衝液により洗浄した。次に細胞を、溶解緩衝液により溶解し、p-ERK/ERKについて製造業者(Mesoscale discovery、カタログ番号K15107D-3)の指示に従い処理及び分析した。本発明の化合物に関するIC50範囲は、下記表4に示している。
イオンチャネルhErg(又はKv11.1)電流の阻害は、QT間隔の延長を引き起こし、これはトルサード・ド・ポワンツ型心室頻脈と称される死に至る可能性のある心室性不整脈を生じる。これは心毒性の主な原因のひとつであり、且つhErgチャネル活性は通常、心毒性リスクを緩和するための創薬過程において早期に評価される。
本発明の化合物は、既知のSHP2阻害剤SHP-099及びRMC-4550と比べ、hErg活性(パッチクランプアッセイにおけるKi)と細胞活性(KYSEにおけるIC50)の間の、はるかに優れたスプリット(split)を示している。このことは、対象へ投与された場合に心毒性の尤度がより少ないと解釈されるべきである。
雌のCD1マウス(N=3)は、化合物の単回の経口(強制飼養)又は単回の静脈内(ボーラス)注射を受け取った。投薬ビヒクルは通常は、経口強制飼養によりクエン酸ナトリウム緩衝液、0.1M、pH3.0中の0.5%Methocel K4M/0.25%Tween20として、又はIV投与に関しては、酢酸ナトリウム緩衝液、0.01M、pH4.5中の10%Kolliphor HS15溶液として与えた。連続した血液試料を、0.083(IV)、0.25、0.5、1、2、4、6及び24時間後に動物からイソフルラン吸入下で舌下から採取し、並びに血漿を得るために更に処理した。試料は、タンパク質を沈殿させ、LC/MS/MSにより分析した。
マウスPKにおいて、本発明の化合物(番号27及び95)は、参照化合物SHP-099と比べ、より低いクリアランス及びより高い曝露を示している。
化合物の選択は、実施例3において説明したものと同じ条件を使用し、しかし活性化ペプチドIRSI_2pY(New England Peptide、140nM)を添加及び非添加した、自己活性化された変異体タンパク質SHP2のE76Kにより、生化学アッセイにおいて試験した。
選択した化合物を、単球細胞(U937)におけるサイトカイン放出アッセイにおいて試験し、それらの抗炎症特性を試験した。細胞を、無血清培地を使用し、96-ウェル細胞培養プレートに播種した。細胞を、指定された濃度のSHP-2阻害剤で30分間処理し、引き続き組換えIL-6(50ng/ml)で一晩刺激した。培養上清中のMCP-1生成を、MCP-1 AlphaLISAキット(Perkin Elmer)を用いて測定した。
再蒸留水3L中の本発明の化合物100g及びリン酸水素二ナトリウム5gの溶液を、2N塩酸を用いてpH6.5に調節し、無菌条件下で濾過し、注射用バイアルへ移し、無菌条件下で凍結乾燥させ、無菌条件下で密封する。各注射用バイアルは、本発明の化合物5mgを含有する。
溶液を、再蒸留水中940mlの、本発明の化合物1g、NaH2PO4・2H2Oの9.38g、Na2HPO4・12H2Oの28.48g、及び塩化ベンザルコニウム0.1gから調製する。pHを6.8に調節し、溶液を1Lとし、照射により滅菌する。
再蒸留水60L中の本発明の化合物1kgの溶液を、無菌条件下で濾過し、アンプルへ移し、無菌条件下で凍結乾燥させ、且つ無菌条件下で密封する。各アンプルは、本発明の化合物10mgを含有する。
Claims (45)
- 式(I):
R1は、モノシクロアルキル、ビシクロアルキル、モノヘテロシクリル又はビヘテロシクリルであり、そのいずれかは、任意にモノシクロアルキル、ビシクロアルキル、モノヘテロシクリル、又はビヘテロシクリルに結合されたスピロであり、そのモノ-もしくはビ-シクロアルキル及びヘテロシクリルの各々は、C1-C6アルキル、-F、-Cl、-CF3、-NH2、C1-C3アミノアルキル、-OH、C1-C3アルコキシ、C1-C3ヒドロキシアルキル及びフェニルから選択された1~3個の基により、各々任意に及び独立して置換されてよく;
Xは、結合、-NH-又は-N(Me)-であり;
R2は、-F、-Cl、-CF3、C1-C3アルコキシ及びC1-C3アルキルから選択された1~3個の基により置換されている、アリール又はヘテロアリールであり;
R3は、-H、-NH2、-OH、-Cl、-F、-Br、又は-CH3であり;
Yは、-Nであり;並びに
R4及びR5は、独立して-H、-NH2、-OH、C1-C3アルキル、又はC1-C3ヒドロキシアルキルである)
の化合物又はその薬学的に許容される塩。 - 前記R2が、その各々が、-F、-Cl、-CF3、-OCH3及び-CH3から選択される1~3個の基により任意に及び独立して置換されている、フェニル、ピリジン、インドール、2,1,3-ベンゾオキサジアゾール及び1,3-ベンゾジアゾールから選択される、請求項1記載の化合物、又はその薬学的に許容される塩。
- 前記R2が、その各々が、-Cl、-F、-CF3及び-OCH3から選択される1~3個の基により任意に及び独立して置換されている、フェニル及びピリジンから選択される、請求項1又は2記載の化合物、又はその薬学的に許容される塩。
- 前記R4の一方が-Hであり、他方が-OHである、請求項1~3のいずれか一項記載の化合物、又はその薬学的に許容される塩。
- 前記Xが、結合である、請求項1~5のいずれか1項記載の化合物、又はその薬学的に許容される塩。
- 前記Xが、-NCH3-である、請求項1~5のいずれか1項記載の化合物、又はその薬学的に許容される塩。
- 前記Xが、-N-である、請求項1~5のいずれか1項記載の化合物、又はその薬学的に許容される塩。
- 前記R1が、-F、-NH2、及び-CH2NH2から選択された1又は2個の基により各々任意に置換された、シクロヘキシル、シクロペンチル、又はピペリジニルである、請求項10記載の化合物、又はその薬学的に許容される塩。
- 前記R1が、1個の-CH2NH2により置換されたシクロペンチル、1個の-NH2により置換されたシクロヘキシル、又は1個の-Fにより置換されたピペリジンである、請求項11記載の化合物、又はその薬学的に許容される塩。
- 下記式(Ib):
R1は:
R6、R7及びR8の各々は、-H、-F、-Cl、-CF3、C1-C3アルコキシ及びC1-C3アルキルから独立して選択され;
nは、0、1、2、又は3であり;並びに
R9、R10、R11、R12、R13、R14、R15及びR16の各々は、存在する場合、-H、C1-C3アルキル、-NH2、-OH、-Cl、-F、-Br、C1-C3アミノアルキル、C1-C3ヒドロキシアルキル、C1-C3アルコキシ、及びフェニルから独立して選択されるか;或いは
R9、R11、R13及びR16の2つは、一緒に、任意にC1-C3アルキル、-NH2、-OH、-Cl、-F、-Br、C1-C3アミノアルキル、C1-C3ヒドロキシアルキル、C1-C3アルコキシ、及びフェニルから選択される1~3個の置換基により任意に置換された、架橋した二環式複素環系を形成するか;或いは
同じ炭素原子に結合されている、R9、R10、R11、R12、R13、R14、R15、及びR16の2つは、一緒に、C1-C3アルキル、-NH2、-OH、-Cl、-F、-Br、C1-C3アミノアルキル、C1-C3ヒドロキシアルキル、C1-C3アルコキシ、及びフェニルから選択される1~3個の置換基により任意に置換された、単環系又は二環系のスピロシクリルを形成するか;或いは
隣接炭疽原子に結合されている、R9、R10、R11、R12、R13、R14、R15、及びR16の2つは、一緒に、C1-C3アルキル、-NH2、-OH、-Cl、-F、-Br、C1-C3アミノアルキル、C1-C3ヒドロキシアルキル、C1-C3アルコキシ、及びフェニルから選択される1~3個の置換基により任意に置換された、縮合されたカルボシクリル又はヘテロシクリルを形成する)
により示される、請求項1~5のいずれか1項記載の化合物、又はその薬学的に許容される塩。 - 前記R3が、-CH3である、請求項1~21のいずれか1項記載の化合物。
- 前記R3が、-NH2である、請求項1~21のいずれか1項記載の化合物。
- 前記R3が、-Hである、請求項1~21のいずれか1項記載の化合物。
- 前記R3が、-Clである、請求項1~21のいずれか1項記載の化合物。
- 前記R8が、-Hであり、並びにR6及びR7の両方が、-Clである、請求項13~25のいずれか1項記載の化合物。
- 以下からなる群から選択される、請求項1記載の化合物、又はその薬学的に許容される塩:
2-(4-アミノ-4-メチルピペリジン-1-イル)-5-(2,3-ジクロロ-フェニル)-ピリミジン-4-カルボキサミド;
6-アミノ-2-(4-アミノ-4-メチル-ピペリジン-1-イル)-5-(3-クロロ-フェニル)-ピリミジン-4-カルボン酸アミド;
6-アミノ-2-(4-アミノ-4-メチル-ピペリジン-1-イル)-5-(2,3-ジクロロ-フェニル)-ピリミジン-4-カルボン酸アミド;
6-アミノ-2-(4-アミノ-4-メチル-ピペリジン-1-イル)-5-(3-フルオロ-フェニル)-ピリミジン-4-カルボン酸アミド;
6-アミノ-2-[(3S,4S)-4-アミノ-3-メチル-2-オキサ-8-アザスピロ-[4.5]デカン-8-イル]-5-(2,3-ジクロロフェニル)ピリミジン-4-カルボキサミド;
6-アミノ-2-{9-アミノ-3-アザビシクロ[3.3.1]ノナン-3-イル}-5-(2,3-ジクロロフェニル)ピリミジン-4-カルボキサミド;
6-アミノ-2-[(1R)-1-アミノ-8-アザスピロ[4.5]デカン-8-イル]-5-(2,3-ジクロロフェニル)ピリミジン-4-カルボキサミド;
6-アミノ-2-[(1R)-1-アミノ-3,3-ジフルオロ-8-アザスピロ[4.5]デカン-8-イル]-5-(2,3-ジクロロフェニル)ピリミジン-4-カルボキサミド;
6-アミノ-2-(4-アミノ-4-メチル-ピペリジン-1-イル)-5-(2,3-ジクロロ-フェニル)-ピリミジン-4-カルボン酸メチルアミド;
6-アミノ-2-[6-アミノ-7-ヒドロキシ-1-(プロパン-2-イル)-2-アザスピロ[3.4]オクタン-2-イル]-5-(2,3-ジクロロフェニル)ピリミジン-4-カルボキサミド;
6-アミノ-2-[8-(アミノメチル)-6-アザスピロ[3.4]オクタン-6-イル]-5-(2,3-ジクロロフェニル)ピリミジン-4-カルボキサミド;
6-アミノ-2-[3-(アミノメチル)-8-アザビシクロ[3.2.1]オクタン-8-イル]-5-(2,3-ジクロロフェニル)ピリミジン-4-カルボキサミド;
6-アミノ-5-(2,3-ジクロロフェニル)-2-[(1R,7S,11s)-11-アミノ-1,7-ジメチル-9-アザビシクロ[5.3.1]ウンデカン-9-イル]ピリミジン-4-カルボキサミド;
6-アミノ-5-(2,3-ジクロロフェニル)-2-[(1R,7S,11r)-11-アミノ-1,7-ジメチル-9-アザビシクロ[5.3.1]ウンデカン-9-イル]ピリミジン-4-カルボキサミド;
2-(4-アミノ-4-メチル-ピペリジン-1-イル)-5-(2,3-ジクロロ-フェニル)-6-ヒドロキシ-ピリミジン-4-カルボン酸アミド;
2-(4-アミノ-4-メチル-ピペリジン-1-イル)-6-クロロ-5-(2,3-ジクロロ-フェニル)-ピリミジン-4-カルボン酸アミド;
6-アミノ-2-(4-アミノ-4-メチル-ピペリジン-1-イル)-5-(2,3-ジクロロ-フェニル)-ピリミジン-4-カルボン酸(2-ヒドロキシ-エチル)-アミド;
2-(4-アミノ-4-メチル-ピペリジン-1-イル)-5-(2,3-ジクロロフェニル)-6-メチル-ピリミジン-4-カルボン酸アミド;
2-(4-アミノ-4-メチル-ピペリジン-1-イル)-6-クロロ-5-(3-フルオロ-フェニル)-ピリミジン-4-カルボン酸アミド;
6-アミノ-2-(4-アミノ-4-メチル-ピペリジン-1-イル)-5-(2,3-ジクロロ-フェニル)-ピリミジン-4-カルボン酸ヒドロキシアミド;
6-アミノ-2-(4-アミノ-4-メチル-ピペリジン-1-イル)-5-(2,3-ジクロロ-フェニル)-ピリミジン-4-カルボン酸ヒドラジド;
2-(4-アミノ-4-メチル-ピペリジン-1-イル)-6-フルオロ-5-(3-フルオロ-フェニル)-ピリミジン-4-カルボン酸アミド;
6-アミノ-2-[4-(アミノメチル)-8-オキサ-2-アザスピロ[4.5]デカン-2-イル]-5-(2,3-ジクロロフェニル)ピリミジン-4-カルボキサミド;
2-[3a-(アミノメチル)-オクタヒドロ-1H-イソインドール-2-イル]-6-アミノ-5-(2,3-ジクロロフェニル)ピリミジン-4-カルボキサミド;
2-(4-アミノ-4-メチル-ピペリジン-1-イル)-5-(3-フルオロ-フェニル)-6-ヒドロキシ-ピリミジン-4-カルボン酸アミド;
(4P)-6-アミノ-2-(4-アミノ-4-メチルピペリジン-1-イル)-5-(2,3-ジクロロフェニル)ピリミジン-4-カルボキサミド;
(4M)-6-アミノ-2-(4-アミノ-4-メチルピペリジン-1-イル)-5-(2,3-ジクロロフェニル)ピリミジン-4-カルボキサミド;
2-(3-アミノ-シクロヘキシルアミノ)-5-(2,3-ジクロロ-フェニル)-6-メチル-ピリミジン-4-カルボン酸アミド;
6-アミノ-2-[4-アミノ-4-(ヒドロキシメチル)ピペリジン-1-イル]-5-(2,3-ジクロロフェニル)ピリミジン-4-カルボキサミド;
(4M)-2-(4-アミノ-4-メチルピペリジン-1-イル)-5-(2,3-ジクロロフェニル)-6-メチルピリミジン-4-カルボキサミド;
(4P)-2-(4-アミノ-4-メチルピペリジン-1-イル)-5-(2,3-ジクロロフェニル)-6-メチルピリミジン-4-カルボキサミド;
2-[(4-アミノ-シクロヘキシル)-メチル-アミノ]-5-(2,3-ジクロロ-フェニル)-6-メチル-ピリミジン-4-カルボン酸アミド;
2-(7-アミノ-3-オキサ-9-アザ-ビシクロ[3.3.1]ノン-9-イル)-5-(2,3-ジクロロ-フェニル)-6-メチル-ピリミジン-4-カルボン酸アミド;
6-アミノ-2-[8-(アミノメチル)-2-オキサ-6-アザスピロ[3.4]オクタン-6-イル]-5-(2,3-ジクロロフェニル)ピリミジン-4-カルボキサミド;
2-((R)-6-アミノ-2-アザ-スピロ[4.4]ノン-2-イル)-5-(2,3-ジクロロ-フェニル)-6-メチル-ピリミジン-4-カルボン酸アミド;
2-(3-アミノメチル-シクロペンチルアミノ)-5-(2,3-ジクロロ-フェニル)-6-メチル-ピリミジン-4-カルボン酸アミド;
2-((S)-6-アミノ-2-アザ-スピロ[4.4]ノン-2-イル)-5-(2,3-ジクロロ-フェニル)-6-メチル-ピリミジン-4-カルボン酸アミド;
6-アミノ-2-{4-アミノ-1-オキサ-9-アザスピロ[5.5]ウンデカン-9-イル}-5-(2,3-ジクロロフェニル)ピリミジン-4-カルボキサミド;
6-アミノ-2-[4-(3-アミノオキサン-2-イル)ピペリジン-1-イル]-5-(2,3-ジクロロフェニル)ピリミジン-4-カルボキサミド;
6-アミノ-2-[3-(アミノメチル)-2-オキサ-8-アザスピロ[4.5]デカン-8-イル]-5-(2,3-ジクロロフェニル)ピリミジン-4-カルボキサミド;
6-アミノ-2-[4-(アミノメチル)-4-メチルピペリジン-1-イル]-5-(2,3-ジクロロフェニル)ピリミジン-4-カルボキサミド;
2-(4-アミノ-ヘキサヒドロ-シクロペンタ[c]ピロール-2-イル)-5-(2,3-ジクロロ-フェニル)-6-メチル-ピリミジン-4-カルボン酸アミド塩酸塩;
2-(2-アミノメチル-シクロペンチルアミノ)-5-(2,3-ジクロロ-フェニル)-6-メチル-ピリミジン-4-カルボン酸アミド;
2-(3-アミノメチル-3-フルオロ-アゼチジン-1-イル)-5-(2,3-ジクロロ-フェニル)-6-メチル-ピリミジン-4-カルボン酸アミド;
2-(4-アミノ-4-メチル-アゼパン-1-イル)-5-(2,3-ジクロロ-フェニル)-6-メチル-ピリミジン-4-カルボン酸アミド;
2-(2-アミノメチル-アゼチジン-1-イル)-5-(2,3-ジクロロ-フェニル)-6-メチル-ピリミジン-4-カルボン酸アミド;
(4P)-2-[(3R)-3-(アミノメチル)モルホリン-4-イル]-5-(2,3-ジクロロフェニル)-6-メチルピリミジン-4-カルボキサミド塩酸塩;
(4P)-2-[(3S)-3-(アミノメチル)モルホリン-4-イル]-5-(2,3-ジクロロフェニル)-6-メチルピリミジン-4-カルボキサミド塩酸塩;
6-アミノ-2-(4-アミノアゼパン-1-イル)-5-(2,3-ジクロロフェニル)-ピリミジン-4-カルボキサミド;
6-アミノ-2-(4-アミノ-オクタヒドロ-1H-イソインドール-2-イル)-5-(2,3-ジクロロフェニル)ピリミジン-4-カルボキサミド;
6-アミノ-2-[(3R,4R)-3-(アミノメチル)-4-フェニルピロリジン-1-イル]-5-(2,3-ジクロロフェニル)ピリミジン-4-カルボキサミド;
6-アミノ-2-({4-アザスピロ[ビシクロ[2.2.2]オクタン-2,2’-オキサン]-4’-イル}アミノ)-5-(2,3-ジクロロフェニル)ピリミジン-4-カルボキサミド;
6-アミノ-2-(4-アミノ-4-プロピルピペリジン-1-イル)-5-(2,3-ジクロロ-フェニル)ピリミジン-4-カルボキサミド;
6-アミノ-2-[3-(アミノメチル)-3-ヒドロキシアゼチジン-1-イル]-5-(2,3-ジクロロフェニル)ピリミジン-4-カルボキサミド;
6-アミノ-2-[3-(アミノメチル)-3-メチルアゼチジン-1-イル]-5-(2,3-ジクロロフェニル)ピリミジン-4-カルボキサミド;
5-(2,3-ジクロロ-フェニル)-6-メチル-2-(5-メチル-ヘキサヒドロ-ピロロ[3,4-c]ピロール-2-イル)-ピリミジン-4-カルボン酸アミド;
2-(3-アミノ-3-ヒドロキシメチル-アゼチジン-1-イル)-5-(2,3-ジクロロ-フェニル)-6-メチル-ピリミジン-4-カルボン酸アミド;
2-(1-アミノ-5-アザ-スピロ[2.4]ヘプト-5-イル)-5-(2,3-ジクロロ-フェニル)-6-メチル-ピリミジン-4-カルボン酸アミド;
2-(4-アミノ-4-メチル-ピペリジン-1-イル)-5-(1H-ベンゾイミダゾール-4-イル)-ピリミジン-4-カルボン酸アミド;
2-(4-アミノ-4-メチル-ピペリジン-1-イル)-5-ベンゾ[1,2,5]-オキサジアゾール-4-イル-ピリミジン-4-カルボン酸アミド;
6-アミノ-2-(4-アミノ-4-メチル-ピペリジン-1-イル)-5-(7-クロロ-1H-インダゾール-6-イル)-ピリミジン-4-カルボン酸アミド;
5-(2,3-ジクロロ-フェニル)-6-メチル-2-(5-メチル-ヘキサヒドロ-ピロロ[3,4-c]ピロール-2-イル)-ピリミジン-4-カルボン酸アミド;
(5M)-6-アミノ-5-(2,3-ジクロロフェニル)-2-{[(3S,4R)-3-フルオロピペリジン-4-イル]アミノ}-ピリミジン-4-カルボキサミド;
6-アミノ-2-{[(1R,2S)-2-アミノシクロヘキシル]アミノ}-5-(2,3-ジクロロフェニル)-ピリミジン-4-カルボキサミド;
(5P)-6-アミノ-2-[(3S,4S)-4-アミノ-3-メチル-2-オキサ-8-アザスピロ[4.5]デカン-8-イル]-5-(2,3-ジクロロフェニル)-ピリミジン-4-カルボキサミド;
(5M)-6-アミノ-2-[(3S,4S)-4-アミノ-3-メチル-2-オキサ-8-アザスピロ[4.5]デカン-8-イル]-5-(2,3-ジクロロフェニル)-ピリミジン-4-カルボキサミド;
2-(3,9-ジアザ-ビシクロ[4.2.1]-ノン-3-イル)-5-(2,3-ジクロロ-フェニル)-6-メチル-ピリミジン-4-カルボン酸アミド;
6-アミノ-2-(3-アミノアゼチジン-1-イル)-5-(2,3-ジクロロフェニル)-ピリミジン-4-カルボキサミド;
6-アミノ-2-[(1R,5S,6R)-6-(アミノメチル)-3-アザビシクロ-[3.1.0]ヘキサン-3-イル]-5-(2,3-ジクロロフェニル)ピリミジン-4-カルボキサミド;
6-アミノ-2-[2-(アミノメチル)-アゼチジン-1-イル]-5-(2,3-ジクロロフェニル)ピリミジン-4-カルボキサミド;
2-((3aR,4R,6aS)-4-アミノ-ヘキサヒドロ-シクロペンタ-[c]ピロール-2-イル)-5-(2,3-ジクロロ-フェニル)-6-メチル-ピリミジン-4-カルボン酸アミド;
2-((3aS,6aS)-4-アミノ-ヘキサヒドロ-シクロペンタ-[c]ピロール-2-イル)-5-(2,3-ジクロロ-フェニル)-6-メチル-ピリミジン-4-カルボン酸アミド;
2-((3aS,4S,6aR)-4-アミノ-ヘキサヒドロ-シクロペンタ-[c]ピロール-2-イル)-5-(2,3-ジクロロ-フェニル)-6-メチル-ピリミジン-4-カルボン酸アミド;
2-((3aS,4R,6aR)-4-アミノ-ヘキサヒドロ-シクロペンタ[c]ピロール-2-イル)-5-(2,3-ジクロロ-フェニル)-6-メチル-ピリミジン-4-カルボン酸アミド;
2-((3aR,6aR)-4-アミノ-ヘキサヒドロ-シクロペンタ-[c]ピロール-2-イル)-5-(2,3-ジクロロ-フェニル)-6-メチル-ピリミジン-4-カルボン酸アミド;
2-((3aR,4S,6aS)-4-アミノ-ヘキサヒドロ-シクロペンタ-[c]ピロール-2-イル)-5-(2,3-ジクロロ-フェニル)-6-メチル-ピリミジン-4-カルボン酸アミド;
(4M)-2-(4-アミノ-4-メチルピペリジン-1-イル)-6-クロロ-5-(2,3-ジクロロフェニル)-ピリミジン-4-カルボキサミド;
(4P)-2-(4-アミノ-4-メチルピペリジン-1-イル)-6-クロロ-5-(2,3-ジクロロフェニル)-ピリミジン-4-カルボキサミド;
2-((3R,4S)-3-アミノ-4-ヒドロキシ-ピロリジン-1-イル)-5-(2,3-ジクロロ-フェニル)-6-メチル-ピリミジン-4-カルボン酸アミド;
2-(4-アミノ-4-メチル-ピペリジン-1-イル)-5-(2,3-ジクロロ-ピリジン-4-イル)-6-メチル-ピリミジン-4-カルボン酸アミド;
2-(4-アミノ-4-メチル-ピペリジン-1-イル)-5-(2-クロロ-4-フルオロ-フェニル)-6-メチル-ピリミジン-4-カルボン酸アミド;
2-(4-アミノ-4-メチル-ピペリジン-1-イル)-5-(4-クロロ-ピリジン-3-イル)-6-メチル-ピリミジン-4-カルボン酸アミド;
2-((3S,4S)-3-アミノ-4-ヒドロキシ-ピロリジン-1-イル)-5-(2,3-ジクロロ-フェニル)-6-メチル-ピリミジン-4-カルボン酸アミド;
2-[(3S,4S)-4-アミノ-3-メチル-2-オキサ-8-アザスピロ[4.5]デカン-8-イル]-5-(2,3-ジクロロフェニル)-6-メチルピリミジン-4-カルボキサミド;
2-(4-アミノ-4-メチル-ピペリジン-1-イル)-6-メチル-5-ピリジン-4-イル-ピリミジン-4-カルボン酸アミド;
(4M)-2-{[(1S,3R)-3-アミノシクロヘキシル]アミノ}-5-(2,3-ジクロロフェニル)-6-メチルピリミジン-4-カルボキサミド;
(4M)-2-{[(1R,3S)-3-アミノシクロヘキシル]アミノ}-5-(2,3-ジクロロフェニル)-6-メチルピリミジン-4-カルボキサミド;
(4P)-2-{[(1R,3S)-3-アミノシクロヘキシル]アミノ}-5-(2,3-ジクロロフェニル)-6-メチルピリミジン-4-カルボキサミド;
(4P)-2-{[(1S,3R)-3-アミノシクロヘキシル]アミノ}-5-(2,3-ジクロロフェニル)-6-メチルピリミジン-4-カルボキサミド;
6-アミノ-2-(4-アミノ-4-メチル-アゼパン-1-イル)-5-(2,3-ジクロロ-フェニル)-ピリミジン-4-カルボン酸アミド;
2-(4-アミノ-4-メチル-ピペリジン-1-イル)-5-(1H-インドール-3-イル)-6-メチル-ピリミジン-4-カルボン酸アミド;
2-(4-アミノ-シクロヘキシル-アミノ)-5-(2,3-ジクロロ-フェニル)-6-メチル-ピリミジン-4-カルボン酸アミド;
(5M)-2-[(3S,4S)-4-アミノ-3-メチル-2-オキサ-8-アザスピロ[4.5]-デカン-8-イル]-5-(2,3-ジクロロ-フェニル)-6-メチルピリミジン-4-カルボキサミド;
(5P)-2-[(3S,4S)-4-アミノ-3-メチル-2-オキサ-8-アザスピロ[4.5]-デカン-8-イル]-5-(2,3-ジクロロ-フェニル)-6-メチルピリミジン-4-カルボキサミド;
(5M)-2-[(1R)-1-アミノ-3,3-ジフルオロ-8-アザスピロ[4.5]-デカン-8-イル]-5-(2,3-ジクロロ-フェニル)-6-メチルピリミジン-4-カルボキサミド;
(5P)-2-[(1R)-1-アミノ-3,3-ジフルオロ-8-アザスピロ[4.5]-デカン-8-イル]-5-(2,3-ジクロロフェニル)-6-メチルピリミジン-4-カルボキサミド;
(5P)-2-[(3aR,6aS)-3a-(アミノメチル)-オクタヒドロ-シクロペンタ[c]ピロール-2-イル]-6-アミノ-5-(2,3-ジクロロフェニル)-ピリミジン-4-カルボキサミド;
(5M)-2-[(3aR,6aS)-3a-(アミノメチル)-オクタヒドロ-シクロペンタ[c]ピロール-2-イル]-6-アミノ-5-(2,3-ジクロロフェニル)-ピリミジン-4-カルボキサミド;
(5P)-2-[(3aR,7aS)-3a-(アミノメチル)-オクタヒドロ-1H-イソインドール-2-イル]-6-アミノ-5-(2,3-ジクロロフェニル)ピリミジン-4-カルボキサミド;
(5P)-2-[(3aS,7aR)-3a-(アミノメチル)-オクタヒドロ-1H-イソインドール-2-イル]-6-アミノ-5-(2,3-ジクロロフェニル)ピリミジン-4-カルボキサミド;
(5M)-2-[(3aR,7aS)-3a-(アミノメチル)-オクタヒドロ-1H-イソインドール-2-イル]-6-アミノ-5-(2,3-ジクロロフェニル)ピリミジン-4-カルボキサミド;
(5M)-2-[(3aS,7aR)-3a-(アミノメチル)-オクタヒドロ-1H-イソインドール-2-イル]-6-アミノ-5-(2,3-ジクロロフェニル)ピリミジン-4-カルボキサミド;
(5P)-2-[(3aS,6aR)-3a-(アミノメチル)-オクタヒドロ-シクロペンタ[c]ピロール-2-イル]-6-アミノ-5-(2,3-ジクロロフェニル)-ピリミジン-4-カルボキサミド;
(5M)-2-[(3aS,6aR)-3a-(アミノメチル)-オクタヒドロ-シクロペンタ[c]ピロール-2-イル]-6-アミノ-5-(2,3-ジクロロフェニル)-ピリミジン-4-カルボキサミド;
(5P)-6-アミノ-2-[4-アミノ-4-(ジフルオロメチル)ピペリジン-1-イル]-5-(2,3-ジクロロフェニル)-ピリミジン-4-カルボキサミド;
(5M)-6-アミノ-2-[4-アミノ-4-(ジフルオロメチル)ピペリジン-1-イル]-5-(2,3-ジクロロフェニル)-ピリミジン-4-カルボキサミド;
(5P)-6-アミノ-2-[(4S)-4-アミノ-4-メチルアゼパン-1-イル]-5-(2,3-ジクロロフェニル)-ピリミジン-4-カルボキサミド;
(5P)-6-アミノ-2-[(4R)-4-アミノ-4-メチルアゼパン-1-イル]-5-(2,3-ジクロロフェニル)-ピリミジン-4-カルボキサミド;
(5M)-6-アミノ-2-[(4S)-4-アミノ-4-メチルアゼパン-1-イル]-5-(2,3-ジクロロフェニル)-ピリミジン-4-カルボキサミド;
2-(4-アミノ-4-メチル-ピペリジン-1-イル)-5-(2-クロロ-3-トリフルオロメチル-フェニル)-6-メチル-ピリミジン-4-カルボン酸アミド;
6-アミノ-2-[(4-アミノ-シクロヘキシル)-メチル-アミノ]-5-(2,3-ジクロロ-フェニル)-ピリミジン-4-カルボン酸アミド;
(5M)-2-[(1R)-1-アミノ-8-アザスピロ[4.5]デカン-8-イル]-5-(2,3-ジクロロフェニル)-6-メチルピリミジン-4-カルボキサミド;
(5P)-2-[(1R)-1-アミノ-8-アザスピロ[4.5]デカン-8-イル]-5-(2,3-ジクロロフェニル)-6-メチルピリミジン-4-カルボキサミド;
(4M)-2-(4-アミノ-4-メチルピペリジン-1-イル)-5-(2-クロロ-4-フルオロ-3-メトキシフェニル)-6-メチルピリミジン-4-カルボキサミド;
(4P)-2-(4-アミノ-4-メチルピペリジン-1-イル)-5-(2-クロロ-4-フルオロ-3-メトキシフェニル)-6-メチルピリミジン-4-カルボキサミド;
(5P)-6-アミノ-2-[(1S)-1-アミノ-1,3-ジヒドロスピロ[インデン-2,4’-ピペリジン]-1’-イル]-5-(2,3-ジクロロフェニル)ピリミジン-4-カルボキサミド;
(5M)-6-アミノ-2-[(1S)-1-アミノ-1,3-ジヒドロスピロ[インデン-2,4’-ピペリジン]-1’-イル]-5-(2,3-ジクロロフェニル)ピリミジン-4-カルボキサミド;
(5M)-2-[(1S)-1-アミノ-1,3-ジヒドロスピロ[インデン-2,4’-ピペリジン]-1’-イル]-5-(2,3-ジクロロフェニル)-6-メチルピリミジン-4-カルボキサミド;
(5P)-2-[(1S)-1-アミノ-1,3-ジヒドロスピロ[インデン-2,4’-ピペリジン]-1’-イル]-5-(2,3-ジクロロフェニル)-6-メチルピリミジン-4-カルボキサミド;
6-アミノ-2-[(4S)-4-アミノ-4,6-ジヒドロスピロ[シクロペンタ[d][1,3]チアゾール-5,4’-ピペリジン]-1’-イル]-5-(2,3-ジクロロフェニル)ピリミジン-4-カルボキサミド;
2-[(3R)-3-アミノ-3H-スピロ[1-ベンゾフラン-2,4’-ピペリジン]-1’-イル]-5-(2,3-ジクロロフェニル)-6-メチルピリミジン-4-カルボキサミド;
6-アミノ-2-[(3R)-3-アミノ-3H-スピロ[1-ベンゾフラン-2,4’-ピペリジン]-1’-イル]-5-(2,3-ジクロロフェニル)ピリミジン-4-カルボキサミド;
(4M)-2-[(3R)-3-アミノ-3H-スピロ[フロ[2,3-b]ピリジン-2,4’-ピペリジン]-1’-イル]-5-(2,3-ジクロロフェニル)-6-メチルピリミジン-4-カルボキサミド;
(4M)-2-[(3S)-3-アミノ-3H-スピロ[フロ[2,3-b]ピリジン-2,4’-ピペリジン]-1’-イル]-5-(2,3-ジクロロフェニル)-6-メチルピリミジン-4-カルボキサミド;
(4P)-2-[(3R)-3-アミノ-3H-スピロ[フロ[2,3-b]ピリジン-2,4’-ピペリジン]-1’-イル]-5-(2,3-ジクロロフェニル)-6-メチルピリミジン-4-カルボキサミド;
(4P)-2-[(3S)-3-アミノ-3H-スピロ[フロ[2,3-b]ピリジン-2,4’-ピペリジン]-1’-イル]-5-(2,3-ジクロロフェニル)-6-メチルピリミジン-4-カルボキサミド;
(4P)-6-アミノ-2-[(3R)-3-アミノ-3H-スピロ[フロ[2,3-b]ピリジン-2,4’-ピペリジン]-1’-イル]-5-(2,3-ジクロロフェニル)ピリミジン-4-カルボキサミド;
(4P)-6-アミノ-2-[(3S)-3-アミノ-3H-スピロ[フロ[2,3-b]ピリジン-2,4’-ピペリジン]-1’-イル]-5-(2,3-ジクロロフェニル)ピリミジン-4-カルボキサミド;
(4M)-6-アミノ-2-[(3R)-3-アミノ-3H-スピロ[フロ[2,3-b]ピリジン-2,4’-ピペリジン]-1’-イル]-5-(2,3-ジクロロフェニル)ピリミジン-4-カルボキサミド;及び
(4M)-6-アミノ-2-[(3S)-3-アミノ-3H-スピロ[フロ[2,3-b]ピリジン-2,4’-ピペリジン]-1’-イル]-5-(2,3-ジクロロフェニル)ピリミジン-4-カルボキサミド。 - 請求項1~27のいずれか1項記載の化合物を、薬学的に許容される担体、アジュバント及び/又は賦形剤と一緒に含有する、医薬組成物。
- 癌の治療のための、請求項1~28のいずれか1項記載の化合物、又はその薬学的に許容される塩の使用。
- 前記癌が、急性リンパ球性白血病、慢性リンパ球性白血病、急性顆粒球性白血病、副腎皮質癌、膀胱癌、脳腫瘍、乳癌、子宮頸癌、子宮頸部の過形成、絨毛癌、結腸直腸癌、子宮内膜癌、食道癌、本態性血小板増加症、胃部癌、泌尿生殖器癌、神経膠腫、膠芽細胞腫、神経線維腫症、ヘアリーセル白血病、頭頸部癌、ホジキン病、カポジ肉腫、腎臓癌、肺癌、リンパ腫、悪性類癌腫、悪性高カルシウム血症、悪性メラノーマ、悪性膵インスリノーマ、甲状腺髄様癌、メラノーマ、多発性骨髄腫、菌状息肉腫、骨髄性白血病、リンパ球性白血病、神経芽細胞腫、非ホジキンリンパ腫、非小細胞肺癌、骨原性肉腫、卵巣癌、膵臓癌、真性赤血球増加症、原発性脳腫瘍、原発性マクログロブリン血症、前立腺癌、腎細胞癌、横紋筋肉腫、皮膚癌、小細胞肺癌、軟組織肉腫、扁平上皮癌、胃癌、精巣癌、甲状腺癌及びウィルムス腫瘍から選択される、請求項29記載の使用。
- 前記癌が、非小細胞肺癌、小細胞肺癌、頭頸部癌、乳癌、食道癌、胃部癌、結腸直腸癌、膠芽細胞腫、膵臓癌、骨肉腫、メラノーマ及び腎臓癌から選択される、請求項29又は30記載の使用。
- 前記化合物が、1又は複数の追加の治療薬と組合せて投与される、請求項29~31のいずれか1項記載の使用。
- 前記1又は複数の追加の治療薬が、EGFR阻害剤、MET阻害剤、PD-L1阻害剤、MEK1/2阻害剤、TGF-βR経路阻害剤、又はそれらの組合せである、請求項32記載の使用。
- 前記1又は複数の追加の治療薬が、エルビタックス、テポチニブ、アベルマブ、Muc1-TGFβR2 Nb、EGFR-Muc1-ADC、ピマセルチブ、ペムブロリズマブ、ニボルマブ、セミプリマブ、アテゾリズマブ、デュルバルマブ、又はそれらの組合せである、請求項33記載の使用。
- 前述の1又は複数の追加の治療薬が、エルビタックス、テポチニブ、アベルマブ、ピマセルチブ又はそれらの組合せである、請求項34記載の使用。
- 加齢黄斑変性症、クローン病、肝硬変、慢性炎症-関連障害、増殖性糖尿病性網膜症、増殖性硝子体網膜症、未熟児網膜症、肉芽腫症、臓器又は組織の移植に関連した免疫細胞過増殖、炎症性腸疾患、乾癬、関節リウマチ、全身性紅斑性狼瘡(SLE)、レチナール低酸素症に続発する血管過増殖及び血管炎からなる群から選択される疾患又は障害の治療のための、請求項1~19のいずれか1項記載の化合物、又はその薬学的に許容される塩の使用。
- 請求項1~27のいずれか1項記載の化合物、又はその薬学的に許容される塩の有効量を、それを必要とする対象へ投与することを含む、該対象における癌の治療方法。
- 前記癌が、急性リンパ球性白血病、慢性リンパ球性白血病、急性顆粒球性白血病、副腎皮質癌、膀胱癌、脳腫瘍、乳癌、子宮頸癌、子宮頸部過形成、絨毛癌、結腸直腸癌、子宮内膜癌、食道癌、本態性血小板増加症、胃部癌、泌尿生殖器癌、神経膠腫、膠芽細胞腫、神経線維腫症、ヘアリーセル白血病、頭頸部癌、ホジキン病、カポジ肉腫、腎臓癌、肺癌、リンパ腫、悪性類癌腫、悪性高カルシウム血症、悪性メラノーマ、悪性膵インスリノーマ、甲状腺髄様癌、メラノーマ、多発性骨髄腫、菌状息肉腫、骨髄性白血病、リンパ球性白血病、神経芽細胞腫、非ホジキンリンパ腫、非小細胞肺癌、骨原性肉腫、卵巣癌、膵臓癌、真性赤血球増加症、原発性脳腫瘍、原発性マクログロブリン血症、前立腺癌、腎細胞癌、横紋筋肉腫、皮膚癌、小細胞肺癌、軟組織肉腫、扁平上皮癌、胃癌、精巣癌、甲状腺癌及びウィルムス腫瘍から選択される、請求項37記載の方法。
- 前記癌が、非小細胞肺癌、小細胞肺癌、乳癌、食道癌、胃部癌、結腸直腸癌、膠芽細胞腫、膵臓癌、骨肉腫、メラノーマ及び腎臓癌から選択される、請求項37又は38記載の方法。
- 前述の対象に1又は複数の追加の治療薬を投与することを更に含む、請求項37~39のいずれか1項記載の方法。
- 前述の1又は複数の追加の治療薬が、EGFR阻害剤、MET阻害剤、PD-L1阻害剤、MEK1/2阻害剤、TGF-βR経路阻害剤、又はそれらの組合せである、請求項40記載の方法。
- 前記1又は複数の追加の治療薬が、エルビタックス、テポチニブ、アベルマブ、ピマセルチブ又はそれらの組合せである、請求項41記載の方法。
- 請求項1~27のいずれか1項記載の化合物、又はその薬学的に許容される塩の有効量を、それを必要とする対象へ投与することを含む、該対象における増殖性疾患又は障害を治療する方法。
- 前記増殖性疾患又は障害が、加齢黄斑変性症、クローン病、肝硬変、慢性炎症-関連障害、増殖性糖尿病性網膜症、増殖性硝子体網膜症、未熟児網膜症、肉芽腫症、臓器又は組織の移植に関連した免疫細胞過増殖、炎症性腸疾患、乾癬、関節リウマチ、全身性紅斑性狼瘡(SLE)、レチナール低酸素症に続発した血管過増殖及び血管炎からなる群から選択される、請求項43記載の方法。
- 前述の対象に1又は複数の追加の治療薬の有効量を投与することを更に含む、請求項43~44のいずれか1項記載の方法。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP19161323.1 | 2019-03-07 | ||
EP19161323 | 2019-03-07 | ||
US201962879597P | 2019-07-29 | 2019-07-29 | |
US62/879,597 | 2019-07-29 | ||
PCT/US2020/021726 WO2020181283A1 (en) | 2019-03-07 | 2020-03-09 | Carboxamide-pyrimidine derivatives as shp2 antagonists |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2022524759A true JP2022524759A (ja) | 2022-05-10 |
JPWO2020181283A5 JPWO2020181283A5 (ja) | 2023-03-15 |
Family
ID=70057354
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021553031A Pending JP2022524759A (ja) | 2019-03-07 | 2020-03-09 | Shp2アンタゴニストとしてのカルボキサミド-ピリミジン誘導体 |
Country Status (8)
Country | Link |
---|---|
US (2) | US11033547B2 (ja) |
EP (1) | EP3935049A1 (ja) |
JP (1) | JP2022524759A (ja) |
CN (1) | CN113795483A (ja) |
AU (1) | AU2020232026A1 (ja) |
CA (1) | CA3127361A1 (ja) |
IL (1) | IL286077A (ja) |
WO (1) | WO2020181283A1 (ja) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115916194A (zh) | 2020-06-18 | 2023-04-04 | 锐新医药公司 | 用于延迟、预防和治疗针对ras抑制剂的获得性抗性的方法 |
CN115916765A (zh) * | 2020-07-10 | 2023-04-04 | 浙江海正药业股份有限公司 | 吡啶或嘧啶类衍生物及其制备方法和用途 |
AU2021344830A1 (en) | 2020-09-03 | 2023-04-06 | Revolution Medicines, Inc. | Use of SOS1 inhibitors to treat malignancies with SHP2 mutations |
KR20230067635A (ko) | 2020-09-15 | 2023-05-16 | 레볼루션 메디슨즈, 인크. | 암의 치료에서 ras 억제제로서 인돌 유도체 |
US20220370456A1 (en) * | 2021-05-05 | 2022-11-24 | Huyabio International, Llc | Combination therapies comprising shp2 inhibitors and egfr tyrosine kinase inhibitors |
CR20230570A (es) | 2021-05-05 | 2024-01-22 | Revolution Medicines Inc | Inhibidores de ras |
WO2022235870A1 (en) | 2021-05-05 | 2022-11-10 | Revolution Medicines, Inc. | Ras inhibitors for the treatment of cancer |
CN117500811A (zh) | 2021-05-05 | 2024-02-02 | 锐新医药公司 | 共价ras抑制剂及其用途 |
TW202313041A (zh) | 2021-06-09 | 2023-04-01 | 瑞士商諾華公司 | 包含達拉菲尼、曲美替尼和shp2抑制劑之三重藥物組合 |
TW202317100A (zh) | 2021-06-23 | 2023-05-01 | 瑞士商諾華公司 | 包含kras g12c抑制劑的藥物組合及其用於治療癌症之用途 |
CA3224341A1 (en) | 2021-09-01 | 2023-03-09 | Novartis Ag | Pharmaceutical combinations comprising a tead inhibitor and uses thereof for the treatment of cancers |
AR127308A1 (es) | 2021-10-08 | 2024-01-10 | Revolution Medicines Inc | Inhibidores ras |
CN114181159B (zh) * | 2021-12-28 | 2024-02-20 | 南通大学 | 含2,4,5-三取代嘧啶酰肼衍生物及其制备方法与应用 |
WO2023172940A1 (en) | 2022-03-08 | 2023-09-14 | Revolution Medicines, Inc. | Methods for treating immune refractory lung cancer |
WO2023240263A1 (en) | 2022-06-10 | 2023-12-14 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
CN116332908A (zh) * | 2023-03-21 | 2023-06-27 | 杭州医学院 | 一种shp2变构抑制剂及其制备方法和应用 |
Family Cites Families (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4207554A (en) | 1972-08-04 | 1980-06-10 | Med-El Inc. | Method and apparatus for automated classification and analysis of cells |
US4125828A (en) | 1972-08-04 | 1978-11-14 | Med-El Inc. | Method and apparatus for automated classification and analysis of cells |
GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
TR199801530T2 (xx) | 1996-02-13 | 1998-11-23 | Zeneca Limited | VEGF �nhibit�rleri olarak kinazolin t�revleri. |
JP4464466B2 (ja) | 1996-03-05 | 2010-05-19 | アストラゼネカ・ユーケイ・リミテッド | 4―アニリノキナゾリン誘導体 |
GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
GB9714249D0 (en) | 1997-07-08 | 1997-09-10 | Angiogene Pharm Ltd | Vascular damaging agents |
GB9900334D0 (en) | 1999-01-07 | 1999-02-24 | Angiogene Pharm Ltd | Tricylic vascular damaging agents |
GB9900752D0 (en) | 1999-01-15 | 1999-03-03 | Angiogene Pharm Ltd | Benzimidazole vascular damaging agents |
WO2001092224A1 (en) | 2000-05-31 | 2001-12-06 | Astrazeneca Ab | Indole derivatives with vascular damaging activity |
IL153484A0 (en) | 2000-07-07 | 2003-07-06 | Angiogene Pharm Ltd | Colchinol derivatives as angiogenesis inhibitors |
BR0112225A (pt) | 2000-07-07 | 2003-05-06 | Angiogene Pharm Ltd | Composto, composição farmacêutica, uso de um composto, e, processo papa preparar um composto |
JO3517B1 (ar) | 2014-01-17 | 2020-07-05 | Novartis Ag | ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2 |
WO2015107493A1 (en) * | 2014-01-17 | 2015-07-23 | Novartis Ag | 1 -pyridazin-/triazin-3-yl-piper(-azine)/idine/pyrolidine derivatives and and compositions thereof for inhibiting the activity of shp2 |
EP3094629B1 (en) | 2014-01-17 | 2018-08-22 | Novartis AG | 1-(triazin-3-yl/pyridazin-3-yl)-piper(-azine)idine derivatives and compositions thereof for inhibiting the activity of shp2 |
WO2016120355A2 (en) * | 2015-01-30 | 2016-08-04 | Basf Se | Herbicidal phenylpyrimidines |
US10975080B2 (en) | 2015-06-19 | 2021-04-13 | Novartis Ag | Compounds and compositions for inhibiting the activity of SHP2 |
JP6878316B2 (ja) | 2015-06-19 | 2021-05-26 | ノバルティス アーゲー | Shp2の活性を阻害するための化合物および組成物 |
CN107922388B (zh) | 2015-06-19 | 2020-12-29 | 诺华股份有限公司 | 用于抑制shp2活性的化合物和组合物 |
SG10202110874TA (en) | 2016-06-07 | 2021-11-29 | Jacobio Pharmaceuticals Co Ltd | Novel heterocyclic derivatives useful as shp2 inhibitors |
ES2810852T3 (es) | 2016-06-14 | 2021-03-09 | Novartis Ag | Compuestos y composiciones para inhibir la actividad de shp2 |
KR20230156174A (ko) | 2016-07-12 | 2023-11-13 | 레볼루션 메디슨즈, 인크. | 다른자리 입체성 shp2 억제제로서의 2,5-이치환 3-메틸 피라진 및 2,5,6-3치환 3-메틸 피라진 |
EP3490985B1 (en) * | 2016-07-26 | 2020-08-05 | Basf Se | Herbicidal pyrimidine compounds |
EP3515916B1 (en) | 2016-09-22 | 2023-06-07 | Relay Therapeutics, Inc. | Shp2 phosphatase inhibitors and methods of use thereof |
TW201819386A (zh) | 2016-10-24 | 2018-06-01 | 美商傳達治療有限公司 | Shp2磷酸酶抑制劑及其使用方法 |
CA3048340A1 (en) | 2017-01-10 | 2018-07-19 | Novartis Ag | Pharmaceutical combination comprising an alk inhibitor and a shp2 inhibitor |
CN110446709B (zh) | 2017-01-23 | 2023-09-12 | 锐新医药公司 | 作为变构shp2抑制剂的二环化合物 |
AU2018210196B2 (en) * | 2017-01-23 | 2022-06-02 | Revolution Medicines, Inc. | Pyridine compounds as allosteric SHP2 inhibitors |
EA201992253A1 (ru) | 2017-03-23 | 2020-03-31 | Джакобио Фармасьютикалс Ко., Лтд. | Новые гетероциклические производные, применимые в качестве ингибиторов shp2 |
WO2019051084A1 (en) | 2017-09-07 | 2019-03-14 | Revolution Medicines, Inc. | SHP2 INHIBITOR COMPOSITIONS AND METHODS OF TREATING CANCER |
EP3681879A1 (en) | 2017-09-11 | 2020-07-22 | Krouzon Pharmaceuticals, Inc. | Octahydrocyclopenta[c]pyrrole allosteric inhibitors of shp2 |
EP3687997A1 (en) | 2017-09-29 | 2020-08-05 | Relay Therapeutics, Inc. | Pyrazolo[3,4-b]pyrazine derivatives as shp2 phosphatase inhibitors |
NL2019805B1 (en) | 2017-10-26 | 2019-05-06 | Swedish Match Lighters Bv | A child resistant gas lighter |
RU2020123241A (ru) | 2017-12-15 | 2022-01-17 | Революшн Медсинз, Инк. | Полициклические соединения в качестве аллостерических ингибиторов shp2 |
WO2019121373A1 (en) * | 2017-12-20 | 2019-06-27 | Basf Se | Herbicidal pyrimidine compounds |
US20200392161A1 (en) | 2018-02-21 | 2020-12-17 | Relay Therapeutics, Inc. | Shp2 phosphatase inhibitors and methods of use thereof |
BR112020019385A2 (pt) | 2018-03-21 | 2021-03-30 | Relay Therapeutics, Inc. | Inibidores de shp2 fosfatase e métodos de uso dos mesmos |
ES2959616T3 (es) * | 2018-09-19 | 2024-02-27 | Bayer Ag | Hidrazidas de fenilpirimidina sustituidas con efecto herbicida |
TW202028183A (zh) * | 2018-10-10 | 2020-08-01 | 大陸商江蘇豪森藥業集團有限公司 | 含氮雜芳類衍生物調節劑、其製備方法和應用 |
WO2021143823A1 (zh) * | 2020-01-16 | 2021-07-22 | 浙江海正药业股份有限公司 | 吡啶或嘧啶类衍生物及其制备方法和用途 |
CN115916765A (zh) * | 2020-07-10 | 2023-04-04 | 浙江海正药业股份有限公司 | 吡啶或嘧啶类衍生物及其制备方法和用途 |
-
2020
- 2020-03-09 AU AU2020232026A patent/AU2020232026A1/en active Pending
- 2020-03-09 JP JP2021553031A patent/JP2022524759A/ja active Pending
- 2020-03-09 CN CN202080033849.2A patent/CN113795483A/zh active Pending
- 2020-03-09 EP EP20715647.2A patent/EP3935049A1/en active Pending
- 2020-03-09 US US16/813,192 patent/US11033547B2/en active Active
- 2020-03-09 CA CA3127361A patent/CA3127361A1/en active Pending
- 2020-03-09 WO PCT/US2020/021726 patent/WO2020181283A1/en unknown
-
2021
- 2021-04-30 US US17/245,423 patent/US11696916B2/en active Active
- 2021-09-02 IL IL286077A patent/IL286077A/en unknown
Also Published As
Publication number | Publication date |
---|---|
US11696916B2 (en) | 2023-07-11 |
CA3127361A1 (en) | 2020-09-10 |
US11033547B2 (en) | 2021-06-15 |
WO2020181283A1 (en) | 2020-09-10 |
CN113795483A (zh) | 2021-12-14 |
US20200281926A1 (en) | 2020-09-10 |
AU2020232026A1 (en) | 2021-09-02 |
US20220362244A1 (en) | 2022-11-17 |
EP3935049A1 (en) | 2022-01-12 |
IL286077A (en) | 2021-10-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2022524759A (ja) | Shp2アンタゴニストとしてのカルボキサミド-ピリミジン誘導体 | |
JP2022527013A (ja) | Shp2拮抗薬としてのピリミジノン誘導体 | |
JP7089061B2 (ja) | サイクリン依存性キナーゼ阻害剤としての2-アミノ-ピリジンまたは2-アミノ-ピリミジン誘導体 | |
JP6133291B2 (ja) | ピラゾロ[3,4−c]ピリジン化合物と使用方法 | |
JP2023506532A (ja) | Kras突然変異型タンパク質阻害剤 | |
JP2022504352A (ja) | 窒素を含有するヘテロ芳香族誘導体の制御因子、その製造方法及び使用 | |
IL256250A (en) | Hpk1 inhibitors and methods of using them | |
KR20220100879A (ko) | Fgfr 저해제로서의 이환식 헤테로사이클 | |
TW201718546A (zh) | 適用作pim激酶抑制劑之雜環化合物 | |
TW202120501A (zh) | 作為parg抑制劑之4-取代的吲哚及吲唑磺醯胺衍生物 | |
EP3784671B1 (en) | Dual atm and dna-pk inhibitors for use in anti-tumor therapy | |
JP2013501002A (ja) | Sykキナーゼ阻害剤としての化合物および組成物 | |
JP2022532758A (ja) | 二環系誘導体を含む阻害剤、その製造方法及び使用 | |
KR20180021702A (ko) | TBK/IKKε 억제제 화합물 및 이의 용도 | |
CN114163454A (zh) | 含吡啶多环类衍生物抑制剂、其制备方法和应用 | |
KR20220061958A (ko) | Cd38의 억제제로서의 헤테로바이사이클릭 아미드 | |
AU2022401750A1 (en) | Pyrazole derivative, and preparation method therefor and use thereof in medicine | |
US20230117295A1 (en) | Nitrogen containing heterocycles as cdk12 inhibitors | |
CA3225045A1 (en) | Her2 mutation inhibitors | |
KR20230094197A (ko) | 암 치료에 유용한 피롤로[3,2-c]피리딘-4-온 유도체들 | |
TW202043223A (zh) | 做為腺苷受體拮抗劑之5-氮雜吲唑衍生物 | |
JP2022532145A (ja) | 置換ベンズイミダゾロン化合物 | |
RU2815003C2 (ru) | Гетероциклическое соединение | |
WO2024020419A1 (en) | Aza-quinazoline compounds and methods of use | |
CN117940425A (en) | HER2 mutation inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20211008 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220511 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230307 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20230307 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20240416 |